Podcasts about roivant sciences

Vivek Ramaswamy is a biotech entrepreneur, author, and political figure from Cincinnati, Ohio. He founded Roivant Sciences in 2014, focusing on innovative pharmaceutical development, and later co-founded Strive Asset Management. He is a prominent political figure, campaigning for the 2024 US Presidency before endorsing Donald Trump. In 2025, Ramaswamy stepped down from his co-leadership role in President Trump's Department of Government Efficiency (DOGE). Ramaswamy's expected run for Ohio governor has reshaped the state's political landscape, with endorsements from prominent Republicans and a platform centered on tax reforms and reducing government inefficiency. Shawn Ryan Show Sponsors: https://lumen.me/srs https://ShawnLikesGold.com | 855-936-GOLD #goldcopartner https://ROKA.com | Use Code SRS https://www.armra.com/srs http://helixsleep.com/srs https://americanfinancing.net/srs NMLS 182334, nmlsconsumeraccess.org This episode is sponsored by BetterHelp. Give online therapy a try at http://betterhelp.com/srs and get on your way to being your best self. Vivek Ramaswamy Links: TikTok - https://www.tiktok.com/@vivekramaswamy Instagram - https://www.instagram.com/vivekgramaswamy/ X - https://x.com/VivekGRamaswamy LinkedIn - https://www.linkedin.com/in/vivekgramaswamy/ Please leave us a review on Apple & Spotify Podcasts. Vigilance Elite/Shawn Ryan Links: Website | Patreon | TikTok | Instagram | Download Learn more about your ad choices. Visit podcastchoices.com/adchoices

Synopsis: Discover how Bitterroot Bio is poised to revolutionize cardiovascular health in this captivating conversation between host Rahul Chaturvedi and CEO Pavan Cheruvu. Pavan opens up about his inspiring journey from engineering to leading a biotech company at the forefront of cardio-immunology. Learn how his visionary leadership is driving innovative solutions to combat atherosclerosis—one of the world's deadliest diseases. Delve into Bitterroot Bio's cutting-edge approach, blending scientific breakthroughs with bold strategies to create life-saving treatments while overcoming the hurdles of drug development in an ever-changing biotech landscape. Biography: Dr. Pavan K. Cheruvu is the President and Chief Executive Officer at Bitterroot Bio. Prior to joining Bitterroot, Dr. Cheruvu was an early member of the executive team at Roivant Sciences and served as President and CEO of Sio Gene Therapies. Over the course of his career, he has worked with multiple biotechnology and medical device companies, as well as in the public sector, with focus areas spanning neurology, oncology, women's health, and cardiology. Dr. Cheruvu previously worked as a management consultant at McKinsey & Company, where he focused on R&D strategy and transformation for biopharmaceutical firms across North America, Asia, and Europe. Dr. Cheruvu holds a BS in biomedical engineering, electrical engineering, and chemistry from Duke University and an MSc in computer science from the University of Oxford, where he was a Rhodes Scholar. He went on to earn an MD from Harvard Medical School and MIT. Dr. Cheruvu completed his residency in internal medicine at Johns Hopkins Hospital and continued his training as a clinical fellow in cardiovascular medicine at the University of California, San Francisco. He currently resides in the San Francisco Bay Area with his wife and daughter. He serves on the Executive Leadership Team of the American Heart Association's Research Roundtable, and the Board of Advisors of Life Sciences Cares Bay Area.

In today's special edition of The Roundtable, Ryan Williams, President of the Claremont Institute interviews Vivek Ramaswamy about his latest book "Truths: The Future of America First." Buy the book here. In "Truths: The Future of America First," Ramaswamy shows exactly how honesty about the most important issues will get our country back on track. The America First movement emphasizes the issues that bring us together, not what divides us. It asks that we put our country over politics, merit over grievance, and truth over lies. Ramaswamy tells us the truth about our political system, and the people who control it, and exhorts us to exercise our right to self-governance again. Vivek is an American business leader and New York Times bestselling author of "Woke, Inc.," as well as "Nation of Victims," "Capitalist Punishment," and most recently "Truths: The Future of America First." Left leaning media has called him one of the “intellectual godfathers of the anti-woke movement” (Politico) and the “right's leading anti-ESG crusader” (Axios and Bloomberg). He was dubbed “The C.E.O. of Anti-Woke,” by The New Yorker. Vivek is the Founder and Executive Chairman of Roivant Sciences. He is a former U.S. Presidential Candidate (R). He was born in Cincinnati to Indian parents. In high school he was class valedictorian, a nationally ranked junior tennis player and an accomplished pianist. He lives in Ohio with his wife and two sons.  Learn more about Vivek Ramaswamy's work here.

Dr. Jordan B. Peterson sits down with author, podcaster, and patriot Vivek Ramaswamy. They discuss his new book (releasing September 24th), “Truths: The Future of America First.” In this episode, they explore the reality of God, the fundamental nature of the sexual binary, how the Left has crafted a new belief system out of paradoxical claims, and how biblical morality is intrinsic to the fabric of America. Vivek Ramaswamy is an American business leader, New York Times bestselling author, and former 2024 Republican U.S. presidential candidate. Born and raised in Cincinnati, Ohio, he went on to become a serial entrepreneur and CEO who founded several successful businesses including Roivant Sciences, Strive, and Chapter. He is a bestselling author of three books — “Woke, Inc.” (2021), “Nation of Victims” (2022), and “Capitalist Punishment” (2023) — with a fourth book coming in 2024, “Truths: The Future of America First.” In 2023, Vivek served as an executive producer on the film “City of Dreams,” which addresses human trafficking and child slavery in the United States. He is a graduate of St. Xavier High School, Harvard College, and Yale Law School. This episode was filmed on September 5th, 2024  - Links - For Vivek Ramaswamy: Preorder Truths: The Future of America First 

In this special student-hosted episode of the “Weinberg in the World” podcast, student host Seora Kim, a junior majoring in economics, interviews Keith Haan, the senior vice president at Roivant Sciences. Keith graduated with a major in Biological Studies. Keith shares his journey from studying biology and playing baseball at Northwestern University to working in a lab at the medical school, which influenced his career path. He discusses his research on B cell signaling and Epstein-Barr virus, and how his interest in biotechnology led him to the finance industry. Keith explains his transition from equity research to venture capital and portfolio management, highlighting the interdisciplinary nature of his career! https://www.linkedin.com/in/keith-haan-9886a069/ Transcript: Seora Kim: Welcome to the Weinberg in the World podcast where we bring stories of interdisciplinary thinking in today's complex world. My name is Seora Kim, and I am your student host of this special episode of the podcast. I am a junior majoring in economics and minoring in data science and global health studies. Today, I am excited to be speaking with Keith Haan, who is the senior vice president at Roivant Sciences. Thank you, Keith, for taking the time to speak with me today. Keith Haan: Thank you, Seora. I'm happy to be here. Seora Kim: Awesome. To start us off today, I'm wondering if you can tell us a little bit more about your time at Northwestern as an undergraduate. What did you study? What were the impactful experiences for you that led to your current career path? Keith Haan: I was an undergraduate major in biology sort of focusing on cell and molecular biology, but my experience at Northwestern was also shaped a lot by the fact that I played baseball for Northwestern. And as part of trying to figure out what to do for the summers, the athletic department does have reach out, and certainly when I was going there, had reach out to sort of help place students with internships that would be interesting. And I ended up working doing research in a lab at the medical school a couple of summers. And I think that really influenced sort of where I wanted to go, and I ended up going and getting my PhD at the grad school down at the medical school campus. Seora Kim: Awesome. That is amazing. Can I ask a little bit more about what kind of research you did at the medical school that helped you pivot? Keith Haan: Yeah, so I worked in a lab that had two focuses. One was on B cell signaling and one was on the cellular factors that allowed Epstein-Barr virus to enter cells. So the two were sort of related. Epstein-Barr virus encodes some proteins that sort of co-opt B cell signaling, and so part of the group focused on that. And then another group of which I was part of really studied the host cell proteins that were involved in mediating entry of the virus to the cell. Seora Kim: Amazing. That sounds super cool. And I was also wondering, were there any pivotal moments for your decisions that shaped your different parts of your journey in your career path? Because I know that you had several experiences before coming to Roivant Sciences. Keith Haan: Yeah, so I would say during grad school, viral entry was a hot topic and was actually very topical for HIV entry and HIV treatments. And so, because some of those newer drugs were being studied in the clinic at that point in time, it sort of got me interested in the biotechnology field in general. But I was also looking at the company and saying, "Hey, this is a company that I think I know well because I understand viral entry well. It's a publicly traded company. That is also interesting." And so, I think given the pace of where the biotech field, where it was going and looking at equities as a way to really be exposed to a lot of what the industry was doing, not just from a single company standpoint, but from an industry-wide standpoint, I got interested in biotech stocks. Which led me into the finance industry starting in equity research, and then moving on in my career to being a partner at a venture firm, and then portfolio manager at a hedge fund. Seora Kim: Awesome. That is super cool because I know that there's a lot of students at Northwestern interested in like economics or finance, but then also the bio side of things. So it's super cool to learn about your experience and how you combined biology as well as finance-related careers in your path and how you did biotech-related stocks equity research. So can you share a little bit more about what you think was the most attractive elements in each part of those roles, like was the more interesting parts in equity research or venture capital's portfolio management, so the students can understand what are differences between those jobs? Keith Haan: Sure. So I can start with the equity research first. It was my foray into finance, and that time was really sort of spent leveraging what I knew and what I had gained just in either biological insights and then translating that to how I thought value could be created from companies. And obviously, at that point in time, there was a pretty big backfill for me in learning the financial building models. I mean, that was something that I had not done at Northwestern. So that was a very good learning experience to be able to combine both as well as to learn how stocks move independent of what you might consider to be an intrinsic value. So that whole learning experience I thought was very valuable. And ultimately, I wanted to be able to, instead of being on the analytical side in equity research, I wanted to move on to being in a place where I could be deploying capital against those ideas. And where my initial interest was, it was sort of the earlier stage, probably earlier in the clinic or preclinical, which was more attuned to what I had learned in my background in my PhD, but also in the small company and the company formation. And so, I chose to go to a venture capital firm where I thought I could really build on the skills that I had already developed in equity research. Seora Kim: Definitely. So I think something that is really interesting is that you're focusing on biotech stocks or biology related financials. So can you share a little bit more about what is different between regular stocks or health tech stocks with biotech stocks? Keith Haan: I think one thing that is different about the biotech sector in general is it is something that is, first of all, highly volatile. There can be very large price swings depending on whether the results from a clinical trial allows a company to move forward to the next step of the clinical studies or to get approved. And when you are putting things in the human body, sometimes you get the results you are expecting and sometimes you don't. So there is a lot of volatility around just those stocks in general. And because of that, it is not something that a lot of funds will necessarily allocate a lot of time or people to, unless they have people that have deep experience doing it. So it is, as opposed to funds that may have a lot of their portfolio invested in tech or other industries that are a little bit better understood, healthcare is a little bit [inaudible 00:08:22], and biotech in particular is a little bit different. Seora Kim: Totally. That makes a lot of sense. And since you mentioned it requires a lot of knowledge and also because of the clinical trial stages, do you think that it's important for students who want to focus on biotech related finance roles to do bio majors or PhD? Or what kind of level of education would be required for these kind of roles? Keith Haan: I think it is helpful, but I have sat next to incredibly intelligent and very, very good people from all different backgrounds. So I have sat next to people that have finance or econ majors and have sort of picked up the biology, the clinical aspects, or the regulatory overlay over time. And then, there are many people that I've worked alongside that have a biology or have a medical background that sort of supplement and backfill with the financial overlay. Seora Kim: Definitely. So it's not necessary to have a bio background, but it can be a very diverse background and anyone who is interested can have a shot at this role? Keith Haan: Yeah, I mean, if you are sort of interested in that nexus, you can come into it from various backgrounds. Seora Kim: Perfect. That's amazing. That's great news for our students. And I guess going on with that, I wanted to learn a little bit more about your current company, Roivant Sciences. So can you maybe elaborate a little bit more on what are some of the current day-to-day in the job right now? Keith Haan: Sure. So in my role, I lead the group that is responsible for the licensing and acquisitions at Roivant. So Roivant is a little bit unique in that the licensing and acquisition plays a very large role in our strategy. So we look really industry-wide and where the innovation is, and a big part of where we find the innovation is external. And so, what we do is try to find collaborators and partner with those assets, and then found very nimble small companies that are really charged with bringing those forward in developing and commercializing them. Seora Kim: Well received. So regarding this kind of business model, would you say your investment strategy or how you find these smaller companies be based on certain criterias or standards? Keith Haan: Yeah, I mean, I think what we ultimately want to do is have something that we believe sort of meets our bar for having a reasonable likelihood of clinical and commercial success. And that can be we can get comfort with that in different ways. But in a lot of instances we can pull from maybe data sets for similar compounds or something has similar mechanism or maybe get comfort from extrapolating some early clinical data. Seora Kim: Sounds good. So regarding that, I think it's super cool to learn about how you bring these smaller companies to the market and commercialize them. Are there any significant trends or innovations currently that you are focused on, or what are some of the recent companies that you've brought on? Keith Haan: I think one of the things that is sort of part of the foundation of Roivant is being nimble and being able to go where the innovation is. So we don't constrain ourselves to looking in a particular therapeutic area or looking at a particular modality, whether it is small molecules or large molecules like antibodies or even other things like gene or cell therapy. What we are looking for is something that can truly be transformative for patients and therefore for Roivant. And the way we are set up, I think we are operationally set up to be able to go where the innovation is and where the field is going. Seora Kim: For sure. So it's super cool to learn how there's no restriction on which specific field that you guys are focused on, but just following the trend of innovation. So was wondering if you could maybe describe what are some of the more recent trend or innovations that you are seeing currently that is kind of the hot field in biotech world? Keith Haan: Yeah, so maybe I can use one of our recent sort of licensing deals to highlight some of those things. So we licensed a program from Pfizer in late in 2022. And part of what drew us to that asset was it had a unique biology where many drugs for inflammatory bowel disease or for inflammatory disorders in general can have the ability to really suppress the immune system. And we saw this asset as something that really had very strong efficacy, some of the strongest efficacy that had been shown in inflammatory bowel disease, but we also thought it maybe had a mechanism that wouldn't be associated with this immune suppression. So I think that was a very strong part of why we decided to bring that asset in. But another layer to that was we also had a biomarker which we felt could predict for even better responses. And I think that is something that really the field is trying to move toward is being able to really deliver the best outcomes for patients. And in inflammatory disorders, that is starting to, I think the field is trying to start to segregate patients who will respond to therapy better. That has been done in oncology, and so there is precedent there. But I think as we learn more about some of these diseases, there's something that certainly we are interested, but also the field is interested in as well. Seora Kim: Totally. That is amazing to learn about. And I think the inflammatory disorders is something that is super important to address, and it's really cool how Roivant Sciences is working towards patient improvement and patient experience. I think it's all leading to a much better world in the healthcare field. So thank you for sharing that example. And to close us out today, I have one last question for you. What do you wish you could tell yourself when you were in our shoes as college students? Keith Haan: Ah. Seora Kim: I'm sorry. Keith Haan: That's a good question. I think I guess what I would probably tell myself is what I would tell students at Northwestern or quite frankly the new employees that are coming into Roivant that are either fresh or relatively fresh out of undergrad is, one is be comfortable that your career is going to be, especially in this field, is going to be really based on sort of a lifetime of learning. It's a field that changes. And as you get more experience, you'll be able to develop expertise in those particular areas, but you will also be exposed to additional things that you might not necessarily have seen before. So just being comfortable with being in a field that is constantly changing and being comfortable with the fact that you just need to sort of be a bit of a lifelong learner. I think I would probably tell my younger self that, but it's something that is also important, and I would say to new employees coming in from undergrad as well. Seora Kim: Totally. That is super helpful for us to consider. Thank you so much for this great advice and for joining us today. Keith Haan: Thank you so much for having me. I appreciate it. Seora Kim: Thank you for listening to this special episode of the Weinberg in the World podcast. We hope you have a great day and go Cats!

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.EPRO, or electronic patient-reported outcomes, is increasingly used in clinical trials to improve data accuracy, patient compliance, and reduce administrative burdens. Swing Therapeutics achieved 98% patient compliance in their pilot trial using EPRO, leading to an FDA de novo marketing authorization. EPRO boosts efficiency, saves costs, and improves trial outcomes.The BioSecure Act, which restricts contracts with certain Chinese companies in the US biotech industry, has advanced in the House but still needs Senate support. Bain Capital closed a $3 billion biotech fund and has been acquiring startup companies. Centessa's sleepiness drug showed promising results, lifting the company's shares. New data raise doubts about AstraZeneca and Daiichi's cancer treatment successor. Candid aims to prove the worth of bispecifics in autoimmune diseases.Roivant Sciences has acquired the rights to develop and commercialize Bayer's pulmonary hypertension drug, Mosliciguat, under an in-license agreement worth up to $294 million. Roivant has created a new "vant" called Vant to focus on this project. The Biosecure Act has passed through the U.S. House of Representatives and is set for a Senate vote. AstraZeneca and Daiichi Sankyo's Dato-Dxd failed to significantly improve overall survival in Phase III NSCLC trials, but there is still potential for FDA approval. Terns Pharmaceuticals announced a $125 million raise following positive Phase I data for their oral GLP-1 candidate for obesity.Old Navy is celebrating its 30th anniversary by throwing back to the '90s in a new collection and campaign to enhance its iconic brand. PayPal has launched its largest-ever US ad campaign featuring Will Ferrell, promoting the use of PayPal for both in-store and online transactions. Angela Zepeda, former Hyundai CMO, has been appointed as the global head of marketing for X. Pizza Hut is turning TikTok content into real-world currency for a promotion in the UAE, while Target is targeting pet owners with a collection designed by "fur-fluencers." Marketers are leveraging AI on mobile platforms and genAI is impacting marketing strategies.Merck's Keytruda, a leading immuno-oncology drug, has been highly successful in treating various cancers and has become the world's top-selling drug. However, determining the true value of a drug like Keytruda involves more than just sales numbers. U.S. drug pricing watchdog ICER tracks pricing decisions and their impact, but the industry is exploring new methods to factor in aspects like disability and income disparity. A new formula that considers "standard of living" is being explored to offer a different perspective on pricing in the pharmaceutical industry. As Keytruda celebrates its 10-year anniversary on the market, the impact of this cancer drug and other immunotherapies is being analyzed, along with the future direction of the field.

Vivek Ramaswamy is a former Presidential Candidate and American entrepreneur. As a Harvard graduate, he founded Roivant Sciences, a wildly successful biotech company. He also co-founded Strive Asset Management, an investment firm that positions itself in opposition to environmental, social, and corporate governance (ESG). Vivek fought a fierce battle on the campaign trail in 2024 and has returned to the Shawn Ryan Show to share his experience and what he believes is next for America. Shawn Ryan Show Sponsors: https://lairdsuperfood.com - USE CODE "SRS" https://shopify.com/shawn https://zippixtoothpicks.com - USE CODE "SRS" Vivek Ramaswamy Links: Instagram - https://www.instagram.com/vivekgramaswamy Twitter - https://twitter.com/VivekGRamaswamy Campaign - https://www.vivek2024.com Please leave us a review on Apple & Spotify Podcasts. Vigilance Elite/Shawn Ryan Links: Website | Patreon | TikTok | Instagram | Download Learn more about your ad choices. Visit podcastchoices.com/adchoices

Patrick Bet-David, Adam Sosnick, Tom Ellsworth & Vincent Oshana are joined by former Presidential candidate Vivek Ramaswamy! Vivek Ramaswamy is an American entrepreneur and politician. He founded Roivant Sciences, a pharmaceutical company, in 2014. In February 2023, Ramaswamy declared his candidacy for the Republican Party nomination in the 2024 United States presidential election THE MINNECT LEAGUE CHAMPIONSHIP: Want your shot to win dinner with Patrick Bet-David? Win "The Minnect League Championship": https://bit.ly/4aMAar8 MINNECT: Connect one-on-one with the right expert for you on Minnect: ⁠⁠⁠⁠https://bit.ly/3MC9IXE⁠⁠⁠⁠ Connect with Patrick Bet-David on Minnect: ⁠⁠⁠⁠https://bit.ly/3OoiGIC⁠⁠⁠⁠ Connect with Adam Sosnick on Minnect: ⁠⁠⁠⁠https://bit.ly/42mnnc4⁠⁠⁠⁠ Connect with Tom Ellsworth on Minnect: ⁠⁠⁠⁠https://bit.ly/3UgJjmR⁠⁠⁠⁠ Connect with Vincent Oshana on Minnect: ⁠⁠⁠⁠https://bit.ly/47TFCXq⁠⁠⁠⁠ Connect with Rob Garguilo on Minnect: ⁠⁠⁠⁠https://bit.ly/426IG0R⁠⁠⁠⁠ CHOOSE YOUR ENEMIES WISELY: Purchase PBD's Book "Choose Your Enemies Wisely": https://bit.ly/41bTtGD BET-DAVID CONSULTING: Get best-in-class business advice with Bet-David Consulting: https://bit.ly/40oUafz VT.COM: Visit VT.com for the latest news and insights from the world of politics, business and entertainment: https://bit.ly/472R3Mz VALUETAINMENT UNIVERSITY: Visit Valuetainment University for the best courses online for entrepreneurs: https://bit.ly/47gKVA0 TEXT US: Text “PODCAST” to 310-340-1132 to get the latest updates in real-time! YOUR NEXT 5 MOVES: Want to be clear on your next 5 business moves? https://bit.ly/3Qzrj3m ABOUT US: Patrick Bet-David is the founder and CEO of Valuetainment Media. He is the author of the #1 Wall Street Journal Bestseller “Your Next Five Moves” (Simon & Schuster) and a father of 2 boys and 2 girls. He currently resides in Ft. Lauderdale, Florida. --- Support this podcast: https://podcasters.spotify.com/pod/show/pbdpodcast/support

Dr. Jordan B. Peterson sits down with 2024 presidential candidate Vivek Ramaswamy to discuss the recent suspension of his campaign, how he fought the traditional media's best advances against him, who he is endorsing now, and the American values he seeks to defend going forward. Vivek Ramaswamy is an entrepreneur, author, and political activist. Vivek has been making headlines since announcing his candidacy for the 2024 presidential election, running on a platform in part to dismantle the expansive and corrupt bureaucracy that has seeped into nearly all facets of American government. Prior to this, Ramaswamy was the founder and CEO of the biopharmaceutical company Roivant Sciences. Leaving in 2021, he published “Woke, Inc.: Inside Corporate America's Social Justice Scam.” In 2022, he co-founded Strive Asset Management with Anson Frericks, which focuses on an alternative to the now-pushed ESG investment framework. That same year Ramaswamy published “Nation of Victims: Identity Politics, the Death of Merit, and the Path Back to Excellence”and has since been deemed one of the “Intellectual Godfathers of the anti-woke movement.”  - Links - 2024 tour details can be found here https://jordanbpeterson.com/events   Peterson Academy https://petersonacademy.com/    For Vivek Ramaswamy: On X https://twitter.com/VivekGRamaswamy?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor On Youtube https://www.youtube.com/@vivek-2024 

“I say this as the kid of legal immigrants: stand for the rule of law. Use our own military to secure our own border,” writes Vivek Ramaswamy – entrepreneur & former Presidential candidate. “We're paving the way for another 9/11-scale tragedy,” says Ramaswamy. “Even if only 0.1% of illegal aliens who've crossed our border have hostile intentions, that's tens of thousands of would-be attackers.” Vivek Ramaswamy is an entrepreneur and author of “Woke, Inc.: Inside Corporate America's Social Justice Scam.” He was a Republican candidate for the 2024 US Presidential Election. He founded the biopharmaceutical company Roivant Sciences in 2014. He is the NYT bestselling author of “Woke, Inc”, “Nation of Victims: Identity Politics, the Death of Merit, and the Path Back to Excellence” and “Capitalist Punishment: How Wall Street is Using Your Money to Create a Country You Didn't Vote For”. Follow him at https://x.com/VivekGRamaswamy 「 SPONSORED BY 」 Find out more about the companies that make this show possible and get special discounts on amazing products at https://drdrew.com/sponsors • COZY EARTH - Susan and Drew love Cozy Earth's sheets & clothing made with super-soft viscose from bamboo! Use code DREW to save up to 40% at https://drdrew.com/cozy • TRU NIAGEN - For almost a decade, Dr. Drew has been taking a healthy-aging supplement called Tru Niagen, which uses a patented form of Nicotinamide Riboside to boost NAD levels. Use code DREW for 20% off at https://drdrew.com/truniagen • PET CLUB 24/7 - Give your pet's body the natural support it deserves! No fillers. No GMOs. No preservatives. Made in the USA. Save 15% at https://drdrew.com/petclub247 • GENUCEL - Using a proprietary base formulated by a pharmacist, Genucel has created skincare that can dramatically improve the appearance of facial redness and under-eye puffiness. Get an extra discount with promo code DREW at https://genucel.com/drew • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at https://twc.health/drew 「 MEDICAL NOTE 」 Portions of this program may examine countervailing views on important medical issues. Always consult your personal physician before making any decisions about your health. 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (https://kalebnation.com) and Susan Pinsky (https://twitter.com/firstladyoflove). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. 「 ABOUT DR. DREW 」 Dr. Drew is a board-certified physician with over 35 years of national radio, NYT bestselling books, and countless TV shows bearing his name. He's known for Celebrity Rehab (VH1), Teen Mom OG (MTV), The Masked Singer (FOX), multiple hit podcasts, and the iconic Loveline radio show. Dr. Drew Pinsky received his undergraduate degree from Amherst College and his M.D. from the University of Southern California, School of Medicine. Read more at https://drdrew.com/about Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Biogen is facing additional troubles as the Department of Justice (DOJ) and Securities and Exchange Commission (SEC) have issued subpoenas seeking more information. The DOJ is specifically looking into the company's overseas operations, while the SEC is investigating the launch of Biogen's now-discontinued Alzheimer's disease therapy, Aduhelm.In other news, the Federal Trade Commission (FTC) and Department of Health and Human Services (HHS) have launched a probe into the ongoing generic drug shortage. The investigation will focus on possible involvement of group purchasing organizations and drug wholesalers in exacerbating the shortage.Ipsen's Onivyde has been approved as a first-line treatment for metastatic pancreatic cancer. This marks the first new frontline treatment option in over 10 years for adults living with this type of cancer.Latigo Biotherapeutics has raised $135 million in a Series A funding round to enter the non-opioid pain medicine space. The company plans to develop its own Nav1.8 inhibitor for pain management.Bristol Myers Squibb is leading the future of protein degradation with its targeted protein degradation approach. The company aims to design next-generation degraders with precision, agility, and intention to attack disease targets.In other funding news, European-based venture capital firm Earlybird Health has closed a $186 million fund focused on cancer and neuroscience investments in biopharma. Additionally, ADC-focused ProfoundBio has raised $112 million in an oversubscribed Series B round.Brivant, a subsidiary of Roivant Sciences, has announced plans to shut down its MDS-focused division, Vant, following disappointing Phase I/II trial results.The FDA has pushed back the Prescription Drug User Fee Act (PDUFA) date for Rocket Pharmaceuticals' gene therapy for a rare blood disorder.Patients taking semaglutide have seen benefits after total hip replacement surgery, according to recent studies.In other news, Novo Nordisk has acquired Catalent's gene therapy manufacturing business for $1.2 billion.These are the top stories in the biopharmaceutical industry today.

Roivant Sciences's Q3 2023 earnings call, unedited

Jack O'Brien discusses what's on tap at Davos with Hackensack Meridian Health CEO Robert Garrett, who's chairing the World Economic Forum's healthcare governance community. Lecia Bushak recaps Roivant Sciences founder Vivek Ramaswamy's decision to drop out of the presidential race, and takes a look back at his campaign. And Christina Applegate's MS-defying appearance at the Emmys tops our Trends segment, along with more TikTok “looksmaxxing” trends and Isabella Strahan's docuseries about battling brain cancer.  Music by Sixième Son.Follow us: @mmmnewsTo read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

Vivek Ramaswamy is a Republican presidential candidate and businessman. In this episode we discuss: Vivek's origin story and early influences Career path and rise to wealth in biotech Why Vivek says Wall Street has seized control of the U.S. economy (theme of his book Capitalist Punishment) The rise of wealth concentration, corporatism and the decline of the American Dream The promise of Bitcoin Bitcoin ETFs and Wall Street adoption A plan to pardon Edward Snowden, Julian Assange, Ross Ulbricht as well as former President Donald Trump Bipartisanship and uniting a divided country He founded pharmaceutical company Roivant Sciences in 2014, and asset management firm Strive in 2022. Vivek also has hedge fund experience and is a bestselling author. He graduated summa cum laude in Biology from Harvard and received his J.D. from Yale Law School.  Follow Vivek on X/Twitter at https://twitter.com/VivekGRamaswamy  Vivek 2024 https://www.vivek2024.com/ Strive https://www.strive.com/  -- Promotional Links: Bitcoin Nashville is July 25-27, 2024: Get 10% off your passes using the code HODL at  https://b.tc/conference CrowdHealth offers the Bitcoin community alternative to health insurance. I now spend just ~$100 a month on my health care. Sign up: https://www.joincrowdhealth.com/natalie  Coinkite is your go-to tech company for top-notch Bitcoin custody solutions, including the cold card wallet. Get 5% off using my link: https://store.coinkite.com/promo/COINSTORIES Buy vaulted gold, silver, and platinum in seconds with OneGold: https://onegold.me/3s6cGg4. Use code COINSTORIESAU for gold and COINSTORIESAG for silver. Fold is the best Bitcoin rewards debit card and shopping app in the world. Get 10,000 satoshis when you sign up and spend $20 on the card:  https://www.foldapp.com/natalie The Orange Pill App is building the social layer for Bitcoin:https://signup.theorangepillapp.com/opa/natbrunell If you're looking for the highest-quality sustainable pork, steak and seafood products, look no further than Campo Grande. For $20 off use code HODL: https://eatcampogrande.com/HODL -- This podcast is for educational purposes and should not be construed as official investment advice. -- VALUE FOR VALUE — SUPPORT NATALIE'S SHOWS Strike ID https://strike.me/coinstoriesnat/ Cash App $CoinStories   #money #Bitcoin #investing

Roivant Sciences Q3 2023 earnings call, unedited

Vivek Ganapathy Ramaswamy is an American entrepreneur and presidential candidate. He founded Roivant Sciences, a pharmaceutical company, in 2014. In February 2023, Ramaswamy declared his candidacy for the Republican Party nomination in the 2024 United States presidential election and has arguably had the strongest performance in the 2023 GOP Presidential primaries. Protect yourself against Central Bank control with - American Hartford Gold https://bit.ly/3QzMjHd Win a signed copy of Vivek's book "Nation of Victims" by answering this question: https://bit.ly/3Qqa5W4 Text PBD to 65532 or call 866-939-6984 Purchase tickets to the PBD Town Hall: Live Meet the Candidate Event with Robert F. Kennedy Jr on December 6th: https://bit.ly/3QRXgoX Connect one-on-one with the right expert to get the answers you need with Minnect! https://bit.ly/468i2VJ Get best-in-class business advice with Bet-David Consulting: https://bit.ly/40oUafz Visit VT.com for the latest news and insights from the world of politics, business and entertainment: https://bit.ly/46a8TMC Visit Valuetainment University for the best courses online for entrepreneurs: https://bit.ly/47gKVA0 Text PBD to 65532 or call 866-939-6984 Subscribe to:  @VALUETAINMENT   @vtsoscast   @ValuetainmentComedy   @bizdocpodcast  Want to get clear on your next 5 business moves? https://valuetainment.com/academy/ Join the channel to get exclusive access to perks: https://bit.ly/3Q9rSQL Download the podcasts on all your favorite platforms https://bit.ly/3sFAW4N Text: PODCAST to 310.340.1132 to get the latest updates in real-time! Patrick Bet-David is the founder and CEO of Valuetainment Media. He is the author of the #1 Wall Street Journal Bestseller Your Next Five Moves (Simon & Schuster) and a father of 2 boys and 2 girls. He currently resides in Ft. Lauderdale, Florida. --- Support this podcast: https://podcasters.spotify.com/pod/show/pbdpodcast/support

Daiichi Sankyo has drawn more value from its antibody-drug conjugate pipeline via a $4 billion deal with Merck & Co. On the latest BioCentury This Week podcast, BioCentury's editors analyze the deal in the context of the burgeoning ADC space and size up the assets that Merck is in-licensing as well as how the deal fits with Daiichi's pipeline strategy.The editors break down Monday's $7.1 billion deal by Roche for the Telavant subsidiary of Roivant Sciences, the latest in the evolving TL1A space; and offer highlights from BioCentury's deep dive into how academics and biotechs are expanding the therapeutic potential of base editors.

US futures are pointing to a lower open as of 04:45 ET. European equity markets had opened mixed to higher but are now largely down, having followed broad weakness in Asian markets. Geopolitics and bond yields remain the main themes. Some discussion of how atypical global macro theme dominance this earnings season is capping gains even on upside surprises. Attention also turns to key tech earnings later this week. Companies Mentioned: Textainer, Roche, Roivant Sciences, Pfizer, Hon Hai

S&P Futures are [using lower this morning as the 10yr Treasury yield hit 5%. Earning and Geopolical issues remain market drives and the dysfunction is Washington DC remains a negative for the markets. This afternoon we have earnings reports due out from WHR, CLF, CCK LOGI & PKG. Chevron announced a deal to acquire Hess in a 53b deal. Roche agreed to buy Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion. In Europe, stocks are moving lower with weakness in the autos, industrials and real estate sectors. Oil prices are slightly lower as a flurry of talks are being held in the Middle East aimed to prevents the Israel / Palestine conflict from expanding.

Rohan Kalahasty is the Co-Founder and CEO of Vytal.ai. He has been a researcher at the Harvard Ophthalmology AI Lab for three years, where he led and incubated NeurOS and worked on projects leveraging mathematical, statistical, and artificial intelligence modeling to enhance eye disease diagnosis. Furthermore, he served as an incubation lead at Roivant Sciences, leading the early stages of a potential new vant. He has also researched at the Center for Brains, Minds, and Machines at MIT, where he dedicated his time to studying human intelligence and memory utilizing artificial intelligence. While working with these groups, he has developed a deep insight into the intersection of AI and Medicine and the creation of digital biomarkers, an insight which has proved crucial for the development of Vytal. He has a focus on interdisciplinary endeavors that have the potential to make an impact in the world. He is a senior at Thomas Jefferson High School for Science and Technology.Sai Mattapali initially focused on behavioral neuroscience, Sai was a research intern at the Neurophysiology Lab at Georgetown University, where he built behavioral paradigms to test auditory learning in Zebrafish. Later pivoting to entrepreneurship and finance, Sai served as a business growth intern at Quantbase (YC W23) and was a part of DMV's Finest, the winners of the Wharton Investment Competition. The amalgamation of his experiences led him to where he is today, leading Vytal with Rohan, with aspirations to be an entrepreneur in the medical space. https://vytal.ai/ Hosted on Acast. See acast.com/privacy for more information.

Alle Infos zu ausgewählten Werbepartnern findest du hier. Das Buch zum Podcast? JETZT BESTELLEN. Lieber als Newsletter? Geht auch. Costco verkauft neuerdings Gold. Netflix verkauft neuerdings keine DVDs. Peloton verkauft neuerdings Lululemon und vice versa. Ansonsten hat CureVac Stress mit BioNTech, AMS-Osram braucht zu viel Geld und bei Schott Pharma läuft. Walmart und Costco kennt jeder. An der Börse ist aber ein anderer Shopping-Club führend - aka BJ's Wholesales Club (WKN: A2JPDX). Roivant Sciences (WKN: A3C4MS) kann mehr als 300% Rendite in zwölf Monaten machen und Milliarden-Medikamente entwickeln. Was aber viel wichtiger ist: Roivant Sciences kann den Präsidentschaftswahlkampf von Vivek Ramaswamy finanzieren. Diesen Podcast vom 29.09.2023, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. Today, we will be discussing the revolutionary potential of artificial intelligence (AI) in scientific research, as well as the latest news in the pharmaceutical and biotech sectors.Artificial intelligence (AI) has the power to transform the work of scientists and become an essential research partner. Pharmaceutical companies and contract research organizations (CROs) are recognizing the need to integrate AI into their labs and workflows to maximize output and scale their research effectively. By utilizing AI technologies, scientists can automate repetitive tasks, analyze large datasets more efficiently, and identify patterns and insights that may not be apparent to the human eye. AI can also assist in data management by organizing and categorizing data, making it easier for scientists to access and utilize information effectively.However, relying solely on data management solutions has its limitations. While data management is crucial, AI offers much more than just organizing information. It provides advanced analytics, machine learning capabilities, and predictive modeling that can significantly enhance research outcomes.To seamlessly transition to AI, it is recommended to implement best practices. This includes ensuring that the data being used is accurate, relevant, and of high quality. It is also important to have a well-defined strategy for integrating AI into existing workflows and infrastructure.In other news, pharmaceutical company Intercept has agreed to be bought out by Italian drugmaker Alfasigma after failing to secure FDA approval for its liver drug. This deal comes at an 82% premium to Intercept's closing price but is still significantly lower than the company's previous valuation of over $7 billion. Immunovant has released data showing the potential of its experimental drug for autoimmune diseases, which could lead to further business development decisions for its parent company, Roivant Sciences. Novo Nordisk has partnered with Evotec in a drug discovery pact focused on metabolic diseases. The collaboration aims to turn early academic research into new development programs. Documents have revealed that FDA staff have "major concerns" about the ALS therapy being developed by BrainStorm, raising doubts about the treatment. Cancer research is advancing and changing the pharma and biotech sectors, while obesity drugs like Ozempic and Wegovy could revolutionize treatment for obesity.Moving on to marketing news, Grubhub is expanding its successful marketing campaign featuring Snoop Dogg to the US. This campaign, titled "Did Somebody Say," generated 4 million views in the first three days of its premiere in the UK. Fruit of the Loom is bringing back its fruit mascots to refresh its TikTok strategy and connect with Gen Z consumers. The brand aims to develop a more meaningful connection with this demographic, which came of age during the characters' TV heyday. iSpot.tv, a TV measurement company, has earned its first-ever accreditation from the Media Rating Council (MRC) for its ad occurrence data. This accreditation could be a step towards broader recognition and validation for the company. Paramount and CBS have launched the Sports Creator Studio ahead of Super Bowl LVIII. The studio aims to connect brands with sports influencers and creators for various content strategies.That's all for today's episode of Pharma and Biotech daily. Thank you for tuning in, and don't forget to visit StudioID's website to learn more about their services. Stay tuned for more important news in the Pharma and Biotech world.

This is a free preview of a paid episode. To hear more, visit andrewsullivan.substack.comVivek is an entrepreneur and a Republican candidate for the 2024 presidential race. He founded a biotech company, Roivant Sciences, after working as an investment partner at a hedge fund. He's also the author of Woke, Inc. and Nation of Victims. I'll get ahead of you guys and confess that I liked him in our chat, and decided I wasn't going to repeat the now-familiar trope of trying to get him to denounce Trump. See what you think, but I learned some stuff about his life.For two clips of our convo — on whether evangelicals will vote for a Hindu, and whether we should let Russia keep the Donbas — pop over to our YouTube page. Other topics: Vivek's upbringing in Cincinnati as the son of Indian immigrants; his engineer dad worked for GE; his mom was a geriatric psychiatrist; he took regular trips to his dad's village in “the boonies of India”; his forebears were British subjects but he doesn't feel oppressed by it; he thinks Americans' view of victimhood is narrow and selective; affirmative action is “structurally embedded” and creates a culture of grievance; Vivek was raised Hindu but went to a Jesuit high school — which in fact strengthened his Hinduism; his faith sees Jesus as a son of God; he defends pluralism and Jefferson; Trump lacks any core values of Christianity; why Vivek went into biotech; how Big Pharma saved my life; his problem with “lurking state action” in the market that disguises its role; his problem with woke capitalism; his goal of reducing the federal workforce by 75 percent; his defense of Taiwan as long as the US is dependent on its semiconductors; why he thinks the CHIPS Act was “poorly executed”; his defense of bilateral trade agreements over multilateral; why “person of color” is as flattening as “LGBTQ”; his thoughts about being a visible minority within the GOP; his reply to the common criticisms against him, including Josh Barro's “that section guy”; and his optimism for the culture war.Browse the Dishcast archive for another convo you might enjoy (the first 102 episodes are free in their entirety — subscribe to get everything else). Coming up: Leor Sapir on the treatment of kids with gender dysphoria, Ian Buruma on his new book The Collaborators: Three Stories of Deception and Survival in World War II, and Spencer Klavan, who wrote How to Save the West: Ancient Wisdom for 5 Modern Crises. Later on: Martha Nussbaum, Matthew Crawford, David Brooks and Pamela Paul. Please send any guest recs, pod dissent and other commentary to dish@andrewsullivan.com.

Vivek Ramaswamy - Best Of First Class Fatherhood - This is a rebroadcast of my interview with Vivek from February 2023.  He will be on the debate stage tonight for the first GOP Presidential Debate.   Vivek Ramaswamy is a First Class Father, Entrepreneur and 2024 Presidential Candidate.  He founded multiple successful enterprises. A first-generation American, he is the founder and Executive Chairman of Roivant Sciences, a new type of biopharmaceutical company focused on the application of technology to drug development. He founded Roivant in 2014 which today has an estimated value of 6.5 Billion dollars.  He is a New York Times bestselling author of “Woke Inc.”, and “Nation of Victims”.  In this Episode, Vivek shares his Fatherhood journey which includes two children.  He discusses why he decided to run for President of the United States.  He describes why restoring the Family Unit is vital to the future success of America.  He talks about wokeism in schools and how parents can fight back against it.  He tells us what he would do first if he was President right now.  He offers some great advice for new or soon-to-be dads and more! Navy SEAL Swim Fundraiser - https://impact.navysealfoundation.org/fundraiser/4796365 The Shawn Ryan Show - https://podcasts.apple.com/us/podcast/shawn-ryan-show/id1492492083 The Alec Lace Show - https://linktr.ee/TheAlecLaceShow My Pillow - https://mystore.com/fatherhood Promo Code: Fatherhood  First Class Fatherhood: Advice and Wisdom from High-Profile Dads - https://bit.ly/36XpXNp Watch First Class Fatherhood on YouTube - https://www.youtube.com/channel/UCCD6cjYptutjJWYlM0Kk6cQ?sub_confirmation=1 More Ways To Listen - https://linktr.ee/alec_lace Follow me on instagram - https://instagram.com/alec_lace?igshid=ebfecg0yvbap For information about becoming a Sponsor of First Class Fatherhood please hit me with an email: AlecLace@FirstClassFatherhood.com

* Guest: Dave Rentschler, CSPOA Regional Director - CSPOA.org * Biden got booed in Maui - He makes it so much worse! - TheBlaze.com * Trump canceled a press conference set for Aug. 21, during which he was going to unveil evidence of fraud in the 2020 presidential election - Saying his lawyers would prefer to put the "irrefutable" evidence in legal filings. * Trump: Skip GOP Debate in Favor of Interview With Tucker Carlson. * The chronic anthem of “machines are not connected to the internet” is being debunked left and right by the Cast Vote Records that our experts have collected, analyzed, and determined absolutely show that the election machines were connected to the internet - FrankSpeech.com * Who is Vivek Ramaswamy? * Vivek is a first-generation American. Growing up in the Cincinnati area, he often recounts the sage advice he received from his father that "If you're going to stand out, then you might as well be outstanding." This advice set the course for his life: an accomplished pianist, a nationally ranked tennis player, and the valedictorian of his Jesuit high school. He went on to graduate summa cum laude in Biology from Harvard in 2007 and received his J.D. degree from Yale Law School in 2013, worked at a hedge fund, then started a pharmaceutical company, Roivant Sciences, where his team developed five drugs that went on to become FDA-approved. * Vivek is an American entrepreneur, political and cultural thought leader, and New York Times bestselling author of Woke, Inc.: Inside Corporate America's Social Justice Scam, along with his second book, Nation of Victims: Identity Politics, the Death of Merit, and the Path Back to Excellence. * Ramaswamy has been a prominent and outspoken critic against ESG, discriminatory practices under the guise of critical race theory, and of what he calls "government-tech censorship," where the government colludes with big tech to do through the backdoor what it couldn't do through the front door under the Constitution. * Vivek Ramaswamy Tells Tucker Carlson FBI, CIA LIED About 9/11, Americans ‘Can't Handle The Truth'! * Vivek Ramaswamy Asked Point Blank If Joe Biden Is A Legitimately Elected President. * TRUTH. There's only one. Not yours, not mine. Just pure TRUTH. In today's bureaucratic political climate where spin is all the Administrative state knows how to do, we stand by cold-hard facts. * Vivek Ramaswamy: God is real, There are two genders, Human flourishing requires fossil fuels, Reverse racism is racism, An open border is no border, Parents determine the education of their children, The nuclear family is the greatest form of governance known to mankind, Capitalism lifts people up from poverty, There are three branches of the US government, not four, The US Constitution is the strongest guarantor of freedoms in history. * America was founded on these truths that we find sacred and undeniable. Without these truths, our standing as a nation would mean nothing. * "Shut down that administrative bureaucracy, shut down the deep state, reduce the federal employee headcount by over 75%.

Shawn Ryan Show is an open platform. Our goal is to bring truth and share untold stories that the media wouldn't otherwise cover. Part of that goal is to give the American people an opportunity to hear from their leaders and prospective leaders in a long format. We're done with the 15 second sound bytes. That's why 2024 Presidential Candidate Vivek Ramaswamy is on this week. Vivek is the son of immigrants turned American success story and entrepreneur. After graduating from Harvard, he founded Roivant Sciences, an incredibly successful biotech company. He would later co-found Strive Asset Management, an investment firm that positions itself in opposition to environmental, social, and corporate governance (ESG). In February of 2023, he announced his candidacy for the Republican Party's nomination for President in the 2024 election. Vivek has been a stark critic of the woke agenda and vows to dismantle the ever elusive deep state. This episode explores his upbringing and his ultimate goal of reestablishing a government for the people, by the people and of the people. Shawn Ryan Show Sponsors: https://preparewithshawn.com https://lairdsuperfood.com - USE CODE "SRS" https://blackbuffalo.com - USE CODE "SRS" https://meetfabric.com/shawn https://1stphorm.com/srs https://ziprecruiter.com/srs Vivek Ramaswamy Links: Instagram - https://www.instagram.com/vivekgramaswamy Twitter - https://twitter.com/VivekGRamaswamy Campaign - https://www.vivek2024.com Please leave us a review on Apple & Spotify Podcasts. Vigilance Elite/Shawn Ryan Links: Website | Patreon | TikTok | Instagram | Download Learn more about your ad choices. Visit podcastchoices.com/adchoices

Dr. Jordan B. Peterson and 2024 presidential candidate Vivek Ramaswamy discuss his ongoing campaign, the long-growing hunger for depth in political discussion, the dire need for a renewed American vision, and how Vivek plans to strip the Washington administrative agencies of their unconstitutional powers. Vivek Ramaswamy is an entrepreneur, author, and political activist. Vivek has been making headlines since announcing his candidacy for the 2024 presidential election, running on a platform in part to dismantle the expansive and corrupt bureaucracy that has seeped into nearly all facets of American government. Prior to this, Ramaswamy was the founder and CEO of the biopharmaceutical company Roivant Sciences. Leaving in 2021, he published “Woke, Inc.: Inside Corporate America's Social Justice Scam.” In 2022, he co-founded Strive Asset Management with Anson Frericks, which focuses on an alternative to the now-pushed ESG investment framework. That same year Ramaswamy published “Nation of Victims: Identity Politics, the Death of Merit, and the Path Back to Excellence.” and has since been deemed one of the “Intellectual Godfathers of the anti-woke movement.”  - Links - For Vivek Ramaswamy: For more information on Vivek's campaign:  https://www.vivek2024.com/  

Episode Notes The band is back together, as Bruce and Jeff reunite to interview Vivek Ramaswamy, co-founder and executive Chairman at Thrive Asset Management. They unravel the problematic mix of politics and big business, as well as Vivek's unconventional path to founding Thrive. They also talk about Thrive's success and what's next. Guest Bio: Vivek Ramaswamy is a first-generation American entrepreneur, investor and New York Times bestselling author. Before founding Strive, he founded multibillion-dollar enterprises including Roivant Sciences, which he led as CEO. Vivek graduated summa cum laude from Harvard and received his law degree from Yale while working as a hedge fund partner.

Vivek Ramaswamy is an entrepreneur and Republican candidate for the 2024 US Presidential Election. He joins Dr. Drew for a LIVE interview about his campaign, his opposition to “woke” policies, the recent Supreme Court ruling on Affirmative Action in colleges, and his experiences as the first Millennial Republican to run for president. Vivek Ramaswamy founded the biopharmaceutical company Roivant Sciences in 2014. He is the NYT bestselling author of “Woke, Inc.: Inside Corporate America's Social Justice Scam”, “Nation of Victims: Identity Politics, the Death of Merit, and the Path Back to Excellence” and “Capitalist Punishment: How Wall Street is Using Your Money to Create a Country You Didn't Vote For”. Find out more at https://vivek2024.com and follow him at https://twitter.com/VivekGRamaswamy 「 SPONSORED BY 」 Find out more about the companies that make this show possible and get special discounts on amazing products at https://drdrew.com/sponsors • PRIMAL LIFE - Dr. Drew recommends Primal Life's 100% natural dental products to improve your mouth. Get a sparkling smile by using natural teeth whitener without harsh chemicals. For a limited time, get 60% off at https://drdrew.com/primal • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at https://drdrew.com/paleovalley • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at https://twc.health/drew • BIRCH GOLD - Don't let your savings lose value. You can own physical gold and silver in a tax-sheltered retirement account, and Birch Gold will help you do it. Claim your free, no obligation info kit from Birch Gold at https://birchgold.com/drew • GENUCEL - Using a proprietary base formulated by a pharmacist, Genucel has created skincare that can dramatically improve the appearance of facial redness and under-eye puffiness. Genucel uses clinical levels of botanical extracts in their cruelty-free, natural, made-in-the-USA line of products. Get an extra discount with promo code DREW at https://genucel.com/drew 「 MEDICAL NOTE 」 The CDC states that COVID-19 vaccines are safe, effective, and reduce your risk of severe illness. You should always consult your personal physician before making any decisions about your health.  「 ABOUT the SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (https://kalebnation.com) and Susan Pinsky (https://twitter.com/firstladyoflove). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. 「 ABOUT DR. DREW 」 For over 30 years, Dr. Drew has answered questions and offered guidance to millions through popular shows like Celebrity Rehab (VH1), Dr. Drew On Call (HLN), Teen Mom OG (MTV), and the iconic radio show Loveline. Now, Dr. Drew is opening his phone lines to the world by streaming LIVE from his home studio. Watch all of Dr. Drew's latest shows at https://drdrew.tv Learn more about your ad choices. Visit megaphone.fm/adchoices

Vivek Ramaswamy is a Republican Presidential Candidate. He is an American entrepreneur, author, and political activist.  In 2022, he co-founded Strive Asset Management and currently serves as the Executive Chairman. Prior to Strive, he founded the biopharmaceutical company Roivant Sciences. Vivek joins Mike to discuss Trump's arraignment in Miami today. Vivek makes some announcements in his press conference from Miami as well.See omnystudio.com/listener for privacy information.

Vivek Ramaswamy is a Republican Presidential Candidate. He is an American entrepreneur, author, and political activist.  In 2022, he co-founded Strive Asset Management and currently serves as the Executive Chairman. Prior to Strive, he founded the biopharmaceutical company Roivant Sciences. Vivek joins Mike to discuss Trump's arraignment in Miami today. Vivek makes some announcements in his press conference from Miami as well.See omnystudio.com/listener for privacy information.

Vivek Ramaswamy is a 2024 Republican presidential candidate who founded biotech company Roivant Sciences, now public. He has written books about what he sees as the excesses of woke capitalism and started an asset management firm called Strive, meant to be a right-wing competitor with BlackRock. With his presidential campaign, Vivek challenges conventional orthodoxy on several core issues, including affirmative action and climate change. Regardless of what you may think about his policies or him, it's worth understanding how he stands to influence our upcoming election and inject his views into the mainstream. If you're looking for an ERP platform, check out our sponsor, NetSuite: http://netsuite.com/upstream -- We're hiring across the board at Turpentine and for Erik's personal team on other projects he's incubating. He's hiring a Chief of Staff, EA, Head of Special Projects, Investment Associate, and more. For a list of JDs, check out: eriktorenberg.com. RECOMMENDED PODCAST:  Every week investor and writer of the popular newsletter The Diff, Byrne Hobart, and co-host Erik Torenberg discuss today's major inflection points in technology, business, and markets – and help listeners build a diversified portfolio of trends and ideas for the future. Subscribe to “The Riff” with Byrne Hobart and Erik Torenberg: https://link.chtbl.com/theriff TIMESTAMPS:  (00:00) Preview of the episode (04:10) When Vivek changed from founder to presidential candidate (11:47) Vivek's presidential platform: Affirmative action, Climate, Fed, Drug crisis (16:34) Sponsors: Secureframe (17:58) Where Vivek overlaps/differs with Silicon Valley: DEI, Free speech, SVB (25:51) Meritocracy above all else? (32:32) How to remove politics from corporations (40:26) Silicon Valley should empathize more with the rest of the country? (56:56) Defining “woke” (58:14) What's it like to run a presidential campaign SOCIAL LINKS: Erik's Twitter: @eriktorenberg Vivek's Twitter: @VivekGRamaswamy Podcast Twitter: @Upstream__Pod Erik's Substack: eriktorenberg.substack.com Please support our sponsors: Shopify | Secureframe  -Shopify: https://shopify.com/torenberg for a $1/month trial period Shopify is the global commerce platform that helps you sell at every stage of your business. Shopify powers 10% of all ecommerce in the US. And Shopify's the global force behind Allbirds, Rothy's, and Brooklinen, and 1,000,000s of other entrepreneurs across 175 countries. From their all-in-one ecommerce platform, to their in-person POS system – wherever and whatever you're selling, Shopify's got you covered. Sign up for $1/month trial period: https://shopify.com/torenberg. - Secureframe: https://secureframe.com/ Secureframe is the leading all-in-one platform for security and privacy compliance. Get SOC-2 audit ready in weeks, not months. I believe in Secureframe so much that I invested in it, and I recommend it to all my portfolio companies. Sign up for a free demo and mention UPSTREAM during your demo to get 20% off your first year.

Vivek Ramaswamy, a 2024 Republican Presidential Candidate, joins us this week for a frank discussion on China, Taiwan, Ukraine, the Dept. of Education, and much more. He's honest, intelligent, charming, and knows the issues inside and out, despite being an actual outsider to the political process. Vivek is an American business leader and New York Times bestselling author of Woke, Inc.: Inside Corporate America's Social Justice Scam, along with his second book, Nation of Victims: Identity Politics, the Death of Merit, and the Path Back to Excellence. Left leaning media has called him the "intellectual godfathers of the anti-woke movement" (Politico) and the “right's leading anti-ESG crusader” (Axios and Bloomberg). He was dubbed "The C.E.O. of Anti-Woke," by the New Yorker and has been described by the Federalist Society as "one of the most compelling conservative voices in the country." These movements are now popularized in mainstream conservative thought. Born and raised in Cincinnati, Ohio, he often recounts the sage advice from his father: “If you're going to stand out, then you might as well be outstanding.” This set the course for his life: a nationally ranked tennis player, and the valedictorian of his high school, St. Xavier. He went on to graduate summa cum laude in Biology from Harvard and received his J.D. from Yale Law School, while working at a hedge fund, then started a biotech company, Roivant Sciences, where he oversaw the development of five drugs that went on to become FDA-approved. In 2022, he founded Strive, an Ohio-based asset management firm that directly competes with asset managers like BlackRock, State Street, Vanguard and others, use the money of everyday citizens to advance environmental and social agendas that many citizens and

Dr. Jordan B. Peterson and Vivek Ramaswamy discuss ESG investing, the culture wars, the upcoming US presidential election, and Vivek's recently announced candidacy. Vivek is an American business leader and New York Times bestselling author of “Woke, Inc.: Inside Corporate America's Social Justice Scam,” along with his second book, “Nation of Victims: Identity Politics, the Death of Merit, and the Path Back to Excellence.” Born and raised in Cincinnati, Ohio, he often recounts the sage advice from his father: “If you're going to stand out, then you might as well be outstanding.” This set the course for his life: a nationally ranked tennis player, and the valedictorian of his high school, St. Xavier. He went on to graduate summa cum laude in Biology from Harvard and received his J.D. from Yale Law School while working at a hedge fund, then started a biotech company, Roivant Sciences, where he oversaw the development of five drugs that went on to become FDA-approved. In 2022, he founded Strive, an Ohio-based asset management firm that directly competes with asset managers like BlackRock, State Street, Vanguard, and others, who use the money of everyday citizens to advance environmental and social agendas that many citizens and capital owners disagree with.

Vivek Ramaswamy is a Republican Presidential Candidate. He is an American entrepreneur, author, and political activist.  In 2022, he co-founded Strive Asset Management and currently serves as the Executive Chairman. Prior to Strive, he founded the biopharmaceutical company Roivant Sciences. Vivek joins Mike to discuss his platform as he is now officially running for President. Where does Vivek stand on all the important issues that America faces? Also, Vivek provides us with some insight on what is happening regarding the Silicon Valley Bank collapse.See omnystudio.com/listener for privacy information.

Vivek Ramaswamy is a Republican Presidential Candidate. He is an American entrepreneur, author, and political activist.  In 2022, he co-founded Strive Asset Management and currently serves as the Executive Chairman. Prior to Strive, he founded the biopharmaceutical company Roivant Sciences. Vivek joins Mike to discuss his platform as he is now officially running for President. Where does Vivek stand on all the important issues that America faces? Also, Vivek provides us with some insight on what is happening regarding the Silicon Valley Bank collapse.See omnystudio.com/listener for privacy information.

Episode 685 - Vivek Ramaswamy is a First Class Father, Entrepreneur and 2024 Presidential Candidate.  He founded multiple successful enterprises. A first-generation American, he is the founder and Executive Chairman of Roivant Sciences, a new type of biopharmaceutical company focused on the application of technology to drug development. He founded Roivant in 2014 which today has an estimated value of 6.5 Billion dollars.  He is a New York Times bestselling author of “Woke Inc.”, and “Nation of Victims”.  He recently announced his campaign to run for President of the United States in 2024. In this Episode, Vivek shares his Fatherhood journey which includes two children.  He discusses why he decided to run for President of the United States.  He describes why restoring the Family Unit is vital to the future success of America.  He talks about wokeism in schools and how parents can fight back against it.  He tells us what he would do first if he was President right now.  He offers some great advice for new or soon-to-be dads and more! Vivek Ramaswamy - https://www.vivek2024.com My Pillow - https://mystore.com/fatherhood Promo Code: Fatherhood  First Class Fatherhood: Advice and Wisdom from High-Profile Dads - https://bit.ly/36XpXNp Watch First Class Fatherhood on YouTube - https://www.youtube.com/channel/UCCD6cjYptutjJWYlM0Kk6cQ?sub_confirmation=1 More Ways To Listen - https://linktr.ee/alec_lace Follow me on instagram - https://instagram.com/alec_lace?igshid=ebfecg0yvbap For information about becoming a Sponsor of First Class Fatherhood please hit me with an email: AlecLace@FirstClassFatherhood.com

Synopsis: Matt Gline is the CEO of Roivant Sciences, a company that delivers innovative medicines and technologies to patients by building Vants – nimble, entrepreneurial biotech and healthcare technology companies. Matt discusses his transition from CFO to CEO at Roivant and how he prepared to step into the CEO role for the first time. He talks about Roivant's model and how it's different from other biotech companies, and how the current market conditions inform how Roivant operates across its portfolio. He also discusses some of the inefficiencies across biotech and where he sees room for improvement, how telemedicine emerged as a silver lining from the pandemic, and his thoughts on the current labor market. Biography: Matthew Gline serves as Chief Executive Officer of Roivant Sciences. Mr. Gline joined Roivant in March 2016 and previously served as Chief Financial Officer. From April 2014 to March 2016, he was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, where he focused on technology and data strategy. Prior to Goldman Sachs, Mr. Gline was a co-founder of Fourthree, a risk analytics technology and consulting company. From 2008 to 2012, he served as Vice President at Barclays, Enterprise Risk Management Advisory, where he provided analysis for corporate clients related to capital markets access for financing and risk management. Mr. Gline earned his A.B. in Physics from Harvard College.

Vivek Ramaswamy is an entrepreneur, investor and author. He founded Roivant Sciences in 2014 and Strive Asset Management in 2021. He's also the author of the bestselling books Woke Inc. and Nation of Victims. Auren and Vivek discuss how CEOs and leaders should think about ideology in the workplace— both their own and their employees'. Vivek breaks down the history of the ESG movement and pulls back the veil on two companies that have massive, little-understood power over the public markets— proxy advisory services ISS and Glass Lewis. Vivek also talks about what drives the pharmaceutical industry and what's holding it back from greater innovation. World of DaaS is brought to you by SafeGraph. For more episodes, visit safegraph.com/podcasts.You can find Auren Hoffman on Twitter at @auren and Vivek Ramaswamy on Twitter at @VivekGRamaswamy

On this week's episode, Vivek Ramaswamy joins She Thinks podcast to help us explore identity politics, specifically the ever-popular mentality of victimhood. We discuss how hardship and striving for excellence became something to shun instead of something to celebrate and why both the left and the right are guilty of victimhood culture. Finally, we address the question of “what do we do?” Is the American Dream a thing of the past, or can we revive the great American experiment?Vivek Ramaswamy is a first-generation American entrepreneur, investor, and New York Times bestselling author. Before founding Strive, he founded multibillion-dollar enterprises including Roivant Sciences, which he led as CEO. Vivek graduated summa cum laude from Harvard, and received his law degree from Yale while working as a hedge fund partner.--She Thinks is a podcast for women (and men) who are sick of the spin in today's news cycle and are seeking the truth. Once a week, every week, She Thinks host Beverly Hallberg is joined by guests who cut through the clutter and bring you the facts. You don't have to keep up with policy and politics to understand how issues will impact you and the people you care about most. You just have to keep up with us. We make sure you have the information you need to come to your own conclusions. Because, let's face it, you're in control of your own life and can think for yourself. You can listen to the latest She Thinks episode(s) here or wherever you get your podcasts. Then subscribe, rate, and share with your friends. If you are already caught up and want more, join our online community. Be sure to subscribe to our emails to ensure you're equipped with the facts on the issues you care about most: https://iwf.org/connect. Independent Women's Forum (IWF) believes all issues are women's issues. IWF promotes policies that aren't just well-intended, but actually enhance people's freedoms, opportunities, and choices. IWF doesn't just talk about problems. We identify solutions and take them straight to the playmakers and policy creators. And, as a 501(c)3, IWF educates the public about the most important topics of the day. Check out the Independent Women's Forum website for more information on how policies impact you, your loved ones, and your community: www.iwf.org. Subscribe to IWF's YouTube channel. Follow IWF on social media: - on Twitter- on Facebook- on Instagram#IWF #SheThinks #AllIssuesAreWomensIssues Hosted on Acast. See acast.com/privacy for more information.

Lindsay Androski serves as President and CEO of Roivant Social Ventures. Shei joined Roivant Sciences as one of its earliest employees, and built and led the team responsible for the in-licensing or acquisition of more than 30 therapeutic programs, resulting in the launch and incubation of 16 subsidiary biotechs and several successful IPOs. Lindsay has likewise demonstrated a longstanding commitment to public service, including by serving on the MIT Alumni Association Board, as Chair of the MIT Annual Fund Board, on the Board of the Women Lawyers Association of LA, and on the Leadership Council of the LA Center for Law and Justice. Roivant Social Ventures has introduced a new model of corporate philanthropy, which couples industry expertise with donor dollars to make an outsized social impact. We provide seed funding and expert advice to startups attacking systemic barriers to health equity. We also launch programs with partners to increase the number of diverse senior executives in biotech and diverse primary investigators. On this episode, we discuss Roivant, Lindsay's upcoming TEDx Event in Dallas in October, the growing ESG movement, creating companies that push a societal good, mental health, and much more. We also welcome back co-host Bob Wierema after his long hiatus from the show! Enjoy. Links: Get your tickets to TEDxVickeryPlace: https://www.tedxvickeryplace.com/event Roivant Social Ventures: https://roivantsv.org/ Lindsay on LinkedIn: https://www.linkedin.com/in/lindsayandroski/ Michael Moore on LinkedIn: https://www.linkedin.com/in/michaelpmoore/ Bob Wierema on LinkedIn: https://www.linkedin.com/in/robert-wierema/ Topics: 1:47) - Welcoming back Co-host Bob Wierema (5:42) - The Alder Initiative (8:06) - Lindsay's background and career (15:48) - Lindsay's social impact fund (21:11) - Europe's influence on America when it comes to ESG (24:23) - The growing ESG movement (26:59) - Reversing the profit-only focus of Big Pharma (38:07) - How would you build a successful company that pushes societal good as well as make money? (41:38) - What are some of the major hurdles in impact investing? (45:06) - What's your take on the world right now and where we are headed? (48:30) - What's the best path philanthropic people can take to make the most impact? (54:24) - What advice do you have for young people to be successful? (59:04) - Thoughts on Mental Health (1:05:42) - What do you want people to know about you?

The band is back together, as Bruce and Jeff reunite to interview Vivek Ramaswamy, co-founder and executive Chairman at Thrive Asset Management. They unravel the problematic mix of politics and big business, as well as Vivek's unconventional path to founding Thrive. They also talk about Thrive's success and what's next.Guest Bio:Vivek Ramaswamy is a first-generation American entrepreneur, investor and New York Times bestselling author. Before founding Strive, he founded multibillion-dollar enterprises including Roivant Sciences, which he led as CEO. Vivek graduated summa cum laude from Harvard and received his law degree from Yale while working as a hedge fund partner.

Today on The Narrative, join Center for Christian Virtue President Aaron Baer and Policy Director David Mahan for the first episode of Volume IV: Woke Capitalism. Listen in as they unpack the latest decision from the U.S. Supreme Court on the Dobbs v. Jackson Women's Health Organization case that overturned the controversial Roe v. Wade. Also joining this week is special guest Vivek Ramaswamy, a first-generation American entrepreneur, investor, and author from southwest Ohio. You'll get the inside scoop on why Christians should not boycott companies that push a progressive agenda, and how it's related to the United States' greatest strength... and greatest weakness. More About Vivek Ramaswamy In 2022, Vivek co-founded Strive, an Ohio-based asset management firm whose mission is to restore the voices of everyday citizens by leading companies to focus on excellence over politics. Prior to Strive, Vivek founded multibillion-dollar enterprises including Roivant Sciences, which he led as CEO for seven years where he oversaw the development of a range of medicines including multiple FDA-approved therapies. He is also the New York Times bestselling author of Woke, Inc.: Inside Corporate America's Social Justice Scam and the forthcoming book Nation of Victims: Identity Politics, the Death of Merit, and the Path Back to Excellence.   To learn more about Center for Christian Virtue and to get involved, visit CCV.org.See omnystudio.com/listener for privacy information.

Woody is the Chief Computational Scientist at Roivant Discovery and former CSO at Silicon Therapeutics. He shared the Roivant Discovery vision for physics-driven drug design and the role of virtual reality to maximize insights. It was an honor to host more than 200 inspiring and engaged attendees. We're grateful to everyone who completed the polls and submitted thoughtful questions.  https://discovery.roivant.com/https://www.linkedin.com/in/woodysherman/

Harry's guest this week is Rohit Nambisan, CEO of Lokavant, a company that helps drug developers get a better picture of how their clinical trials are progressing. He explains the need for the company's services with an interesting analogy: these days, Nambisan points out, you can use an app like GrubHub to order a pizza for $20 or $25, and the app will give you a real-time, minute by minute accounting of where the pizza is and when it's going to arrive at your door. But f you're a pharmaceutical company running a clinical trial for a new drug, you can spend anywhere from $3 million to $300 million—and still have absolutely no idea when the trial will finish or whether your drug will turn out to be effective. Because there's little infrastructure for analyzing clinical trial data in midstream or spotting trouble before it arrives, some studies continue long after they should have been canceled, and positive data sometimes gets thrown out because of minor procedural flaws; in the end, 20 to 30 percent of the money drug makers spend on clinical trials goes down the drain, Nambisan says. Lokavant's platform allows drug makers and clinical research organizations to harmonize the results coming in from study sites, compare it to data from other trials, and discover important signals in the data before it's too late. For example, a company might discover that it's not enrolling patients fast enough to complete a trial on schedule, or that the researchers administering the study aren't following the exact protocols laid out in advance. Such headaches might sound abstract and remote, but poor data management slows down the whole drug development process, which means fewer beneficial new drugs make it to market ever year; that's the ultimate problem Lokavant is trying to fix.Please rate and review The Harry Glorikian Show on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:1. Open the Podcasts app on your iPhone, iPad, or Mac. 2. Navigate to The Harry Glorikian Show podcast. You can find it by searching for it or selecting it from your library. Just note that you'll have to go to the series page which shows all the episodes, not just the page for a single episode.3. Scroll down to find the subhead titled "Ratings & Reviews."4. Under one of the highlighted reviews, select "Write a Review."5. Next, select a star rating at the top — you have the option of choosing between one and five stars. 6. Using the text box at the top, write a title for your review. Then, in the lower text box, write your review. Your review can be up to 300 words long.7. Once you've finished, select "Send" or "Save" in the top-right corner. 8. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed next to any reviews you leave from here on out. 9. After selecting a nickname, tap OK. Your review may not be immediately visible.That's it! Thanks so much.TranscriptHarry Glorikian: Hello. I'm Harry Glorikian, and this is The Harry Glorikian Show, where we explore how technology is changing everything we know about healthcare.My guest Rohit Nimbasan comes from the worlds of biotech and data science. And during our interview he made an interesting point.These days you can use an app like GrubHub to order a pizza for twenty or twenty-five bucks, and the app will give you a real-time, minute by minute accounting of where the pizza is and when it's going to arrive at your door.But Nimbasan points out that if you're a pharmaceutical company running a clinical trial for a new drug, you can spend anywhere from $3 million to $300 million and still have absolutely no idea when the trial will finish or whether your drug will turn out to be effective.The problem is, there's just no infrastructure for analyzing clinical trial data in midstream or spotting trouble before it arrives.As a result, according to Nimbasan, twenty to thirty percent of the money drug makers spend on clinical trials goes down the drain, because of studies that continue long after they should have been canceled, or good data that gets thrown out because of some minor procedural flaw.Nimbasan is the CEO of a company called Lokavant that wants to change all that.The company is building a data platform that allows drug makers and clinical research organizations to harmonize the results coming in from study sites, compare it to data from other trials, and discover important signals in the data before it's too late.For example, a company might discover that it's not enrolling patients fast enough to complete a trial on schedule, or that the researchers administering the study aren't following the exact protocols laid out in advance.All of those problems can increase the cost of a trial.They can even lead regulators to deny approval for a drug that might have proved effective if it had been property tested.For an average healthcare consumer, these kinds of headaches might sound abstract and remote, like something only clinical trial managers would ever have to worry about. But the fact is poor data management slows down the whole drug development process, which means fewer beneficial new drugs make it to market ever year.So I think we should all be cheering companies like Lokavant who are trying to fix the process.Here's my full interview with Rohit.Harry Glorikian: Rohit, welcome to the show.Rohit Nambisan: Thanks, Harry, for having me.Harry Glorikian: You know, you and I sort of talk off and on all the time about the space and what's going on, but, you know, having it on the show, I have to step back and sort of forget everything I know about the company and start from scratch. So, you know, can you explain to people Lokavant's business in a way that would make sense to someone, say, outside of the pharmaceutical industry. In other words, you know, what are the big problems you're solving for organizations that, say, are running a clinical trial, and how are you solving them?Rohit Nambisan: Sure, I can do that. I think it bears noting that we should probably step back a little bit and talk about the industry as a whole and where it's been going, and then I can clarify where Lokavant comes in. So I think as many folks know and for those who don't, I'll fill in the blanks. I know you know this area, but in the last, I'd say 15 to 20 years, we've been moving in pharmaceutical development away from blockbuster medications, things like diabetes type 2. Right, developing therapies for that and getting each drug developer trying to find a smaller piece of market and larger pie to specialized, niche therapeutic indications. Right. So the way I could probably better started with the diabetes example is it's no longer diabetes type 2. It's let's develop the compounds or therapies for diabetes type 2 patients that are comorbid with that have also chronic kidney disease and are metformin naive, meaning they haven't taken a particular therapy known as metformin. Right. So it's a more complex filter criteria, so to speak. Right. And so what happens when the industry moves in that that direction is that when you get into these very niche therapeutic areas, you need to collect particular niche, commensurately niche types of data to validate your hypothesis whether or not this therapy is safe and efficacious through clinical trials. Right. Rohit Nambisan: And in doing that, you now increased the complexity of the trial greatly, not only in terms of the different types of data collecting, but the amount of different types of data you're collecting. So now each trial becomes a lot more specialized. Not just specialized therapeutics, but each trial becomes more specialized. Right? And so for that reason, we've seen a big challenge as we as we moved across that space. And actually, it's been really beneficial for patients because now we're going after, as an industry, we're going after really niche unmet clinical needs that previously there were no therapies for or being developed for. So it's a really good thing for a patient perspective, but from the perspective of development, it makes it that much harder. Not only is there a smaller market opportunity, there's less patients to treat, right, but the complexity, the actual costs of the trial and the complexity of trial has gotten exponentially that much greater. So what Lokavant came out of was we were actually a, shall we say, an internal initiative within Roivant Sciences, which is a company that launches a number of different biotechnology companies and tech companies as well. But better known for biotechnology companies. And we saw a great need to be able to develop therapies for niche indications much faster, much more efficient, much more cost effectively, and also meet the complexities of that trial better through novel data and tech.Rohit Nambisan: And so what Lokavant is essentially, is a data platform that allows drug developers, pharma, therapy developers, to be able to choose which data sources they need, data types they need for a trial. And we can ingest any of those data sources, we can analyze any of those data sources in a holistic manner and expose patterns or signals that could be beneficial or detrimental to the study on an ongoing basis. And when I say ongoing basis, I mean you're not waiting until the end of the study. And I guess the best way I can align this is just like my kids do sometimes. You're not waiting until the last day before your term paper is due, before the project's due to finish your work, you're actually assessing, doing bits of it along the way to assess where there may be challenges, which gives you, really, the time to correct issues to manage your trial better. And frankly, each one of these trials now, there are between, what, $2 million and $300 million we're investing in these single trials at this point. So it's egregious to me that we do not have the toolset to be able to even identify, pull in that data effectively on an ongoing basis to detect these signals so we can plan effectively to do something about it.Harry Glorikian: Anybody who's done a clinical trial knows that there's a lot of risk. Right. So, you know, can you talk about some of the types of risks you're trying to help make sure drug developers diminish, for the most part.Rohit Nambisan: Yeah. So I think the way we start with that is always at the highest level, time, cost and quality, right? So when we talk about time, it's really important to understand that you're going to be able to achieve less. For example, I'll give you a few instances. Target participant accrual, right? Obviously for you to run a trial effectively, you need to have particular types of participants or patients, if it's a sick population. In a vaccine population, they weren't necessarily sick. So that's why I use participants as the term. But you need to make sure that you have path to randomized screening and randomizing these patients for your trial in a given time period. Right. And if that's if your enrollment is is not on track for the countries and the sites you've decided to actually activate the study in, you could, your timeline for your study could be exceptionally extended. Right. So that's that's one type of one example of a thing we look at to understand how the timeline looking for the study. Another area on timeline for example and similarly is discontinuation. So you can you could enroll patients fine. But if you've high volumes of discontinuation of participants in your study, then what ends up happening is you actually don't have as many evaluable subjects in your study of some evaluable participants. So you have to recruit or enroll more subjects, right? So that could extend the timeline as well. One aspect of the timeline that really affects the overall market opportunity is oftentimes these therapies are only in under patient for a certain amount of time. So the faster you can get them to market, the faster you can get recoup your return on investment. But also on the patient side, the faster we can get these therapies out through the market to address unmet clinical needs. That's just one flavor.Rohit Nambisan: Then we have subsequent types of flavors. When we talk about data quality, making sure the data is actually collected in the way that you stated you wanted it to be collected in the plan and the protocol at the outset of the study, as well as cost implications. Right. So we look at cost implications as well, which is how, what will this, what will the extension of enrollment or bad data quality data do to the overall budget that you had planned for this study? But then when you drill down on the level further, you can get into risk categories, is something we look at quite a bit when we look at things like protocol, adherence, when you're when you're collecting this data, as I mentioned, it has to be done per a very prescriptive method that is specified a priori before starting the trial in a protocol. And if it's not collected in that manner, it can be discounted. So we are tracking the risk to protocol deviations and understanding trends and not only understanding trends within that study, but we're looking at similar types of studies in this particular therapy area, neurology or say, psychiatry or gastrointestinal type studies and saying, what has been the protocol adherence in studies like yours? And therefore, can we glean some insights about how you are doing in your study based on your comparators in the study as well? But that's just a small flavor. I could probably wax on for quite some time on this question.Harry Glorikian: Well, that that brings us to the question -- I mean, everything you just said, it brings to the question like, from what I know, the company sort of predicts how clinical trials will go by comparing it against a proprietary data set of, I think I was reading, 2000 past trials, right? So I guess the question becomes, so you're comparing one to the past of things that are similar, but you know, for everybody who's listening sort of, you know, where does that data come from in one sense, is it truly proprietary? I mean, that's what I'm you know, that's my set of questions at the moment.Rohit Nambisan: Sure. So I worked for a while, before coming to the life sciences, in the R&D space and the life sciences commercial space. And I think that data sets, are there are proprietary datasets in that space? Very much so. But there is a third party market for that data a little bit more. So then we find life sciences data. It's really hard to get access to R&D data and as you can imagine, that makes a lot of sense, right? If you're a drug developer or a pharmaceutical developer that successfully completed a trial, you never want to share that data. Thereafter, you spent millions of dollars investing in the study, if you want. If there are potentially unknown issues that you haven't identified, would you want to put that at risk? If you are similarly, if you are a therapeutics developer that didn't meet your endpoints, do you want that information to get out and maybe potentially things that issues that that you should have should not overlook, right, getting out in public, etc.? There's just a lot of business risk. There's also IP risk, right? There's a number of different risks associated with getting that data out. So it's been not a very straightforward journey to aggregate data in life sciences, R&D. That being said, I think how we approached this was we've developed models that are both used for benchmarking, as I mentioned before, comparing against similar trials for particular performance KPIs, so to speak, as well as predictive model generation and machine learning models that require a fair amount of data to train on to actually deliver value.Rohit Nambisan: And in that model, we've talked to a lot of our partners or let's say folks that leads them before their partners. And we talk to them. We say we have a growing dataset. There's precedent for this because we've done this with other partners, number one. Number two, we've worked with them to leverage their data combined with our data, write their enterprise data with our data, because it's a common, it's not just one entity's data that's going to provide that value. Your performance, your processes, the way you run trials is inherent in your data. And if we don't leverage that data to train our model to retrain some parts of our models against, we're not providing you the most value we could be with our predictive models or benchmarking. So with that approach, we've been able to do comparative analysis of our data set versus other people's datasets and then anonymize their data upon having a partnership with them to grow our data assets in a very risk-tolerant manner. Right. All the information about CROs or sponsors or other entities, people running trials is removed from the data and we only leverage that data for the purposes of analytics or generating a benchmark. So none of that data is ever shared. So through that process, over the last, I'd say two years, maybe a little two years and change since we started, we've been able to continuously grow this asset and provide greater and greater value with our descriptive diagnostic predictive analytics as well as our benchmarking.Harry Glorikian: How much money, if you had to guess just to give people like an idea, how much money do you think gets poured down the drain preventably every year, and you could save all this money if you just ran smarter, if you did smarter clinical trial management, if I had to frame it that way.Rohit Nambisan: Oh, at least I would say we've done some back calculations on this and happy to digress into the details of them if warranted, but at least somewhere between 20 to 30 percent of the trial costs right now and depending on the phase and depending on the therapeutic area, again, that could be anywhere from 20 to 30 percent of $3 million to $300 million per study.Harry Glorikian: Yeah. I mean it's you know, that's got to be, I don't know how many billions that is. I can't I don't know exactly how much is being spent annually off the top of my head.Rohit Nambisan: We believe we've done some back of the envelope calculations to show that it is in the billions for sure. Across the across the global pharmaceutical market, we're looking just just the value proposition and the signal detection we're bringing to bear is somewhere around $18 to $20 billion, in terms of market opportunity.Harry Glorikian: I mean, how would you guys run or help a team run a clinical trial in practice? Can you sort of give me a real-world example, maybe de-identified, where you helped the client avoid or mitigate some kind of risk, whether it has to do with patient enrollment or site compliance or safety issues during a trial, any one of those will do.Rohit Nambisan: Sure. So I think one example that I can bring to bear is working with a large CRO. And with this large CRO, they had a sizable data asset that was not harmonized, so to speak. It was still living in the transactional exports from the source data systems or CSPs. Et cetera. All around. So it was they had a bunch of different hypotheses about where they were proficient, where they were deficient, but nothing validated. So we spent some time with them trying to understand what all their data assets looked like. And we started collecting these different representations of former trials and ongoing trials, and we collected them and we harmonized them. In fact, as I mentioned before, one of our major differentiators is this is creation of a single source of truth. And we take that upon ourselves, too. It's not like a service, it's part of our offering, right? Our platform offering. And so what we did was we brought that data together and we it was about, I think 400 to 500 studies worth of data at that point. We harmonized it into what we call our local and canonical data format, which is a single representation for multiple different domains of data, scientific data, operational data, enrollment data, etc. And then we compared that against similar studies in our repository, our growing repository, and said, okay, we can tell you comparatively that you are deficient in these particular areas and you're very proficient at the various--for example, in this case they were very proficient in achieving first patient in on the timeline that they expected to actually, scratch that, that they were very they were very proficient in actually accruing the subjects by last patient in in the time they were expected to write so they could hit their accrual when they wanted to.Rohit Nambisan: But when we looked deeper into the data and looked at across like first patient in, the 50 percent enrollment mark for the study and then last patient in for the study, we were able to identify that there was actually a slowdown and a major overcorrection to make up for that. So they were actually hitting what they needed to hit. But as we all probably know, at least in the clinical research phase and any or any budgeting process, being over your budgeting process is bad. Being under your budgeting process is bad, right? So in this case, it's again the same. They were burning resource and cash and resources to rapidly overcorrect for for a milestone they were not hitting reliably earlier in their studies. And so we realized in that accrual situation we said, okay, what you need is, we've identified an error, you're potentially deficient. What you need is an enrollment forecasting application that brings in the data in real time from your study. Right. And it also combines historical data from our repository in your historical data to seed some prior knowledge about the study. So and it's automated, fully automated. So every day you can understand where you are in relation to where you need to be. Right? And it's not a naive straight line kind of curve. It's basically it's based on looking at thousands of historical studies in this space and understanding what the curvature of the actual model should look like.Rohit Nambisan: So we generated that and we were able to actually, in the proof of concept, and this is just one particular example of an application we've been able to generate from our clinical trial intelligence platform, we generated that and we were able to, on a study, predict two years out within one month when they would actually really hit the accrual and it was within one month accurate. Now while that was valuable in terms of understanding at the end state, what really the value was of this closed loop model, so to speak, right, is that it is closed loop. It allows them in silica to say, what happens if I open some sites here? What happens if I close some sites? So what happens if I close this country here? How will that affect my plan before I put that into action in the real world, which oftentimes is very, very, first of all, it's very risky. But second of all, it can yield a number of unknown consequences if you don't try it before in silico. So I think the approach here was we were able to not only predict these things better and also predict the impact of change orders on the study, that might actually affect the timeline of the study. But we were able to actually provide them an application, an interface by which they could test it all their hypotheses in a virtualized manner before they implemented them. And we're growing like crazy with that, with that partner right now at that point.Harry Glorikian: Yeah. And I mean, I mean, you know, in some ways it sounds like, you know, I didn't get it done and I'm pulling all nighters, like at some point so that I can get it done. Right. So there's a whole staffing model. And how do you bring this to the attention of everybody so that they don't drop the ball? Right, because there's a million other things that might be coming at them at that moment.Rohit Nambisan: That's exactly right. Actually, one thing I'll add to that, given you mentioned the staffing model around it, is that we were born within small biotech. Right. And small biotech is very resource-constrained in its ability to manage and oversee a study. That's fairly well known. So our approach has always been what I'd like to call machine-assisted human intelligence. We have experts that are human experts that know the space, but they need to be augmented. They need to be able to look at more complex streams of information and have a machine pick out particular salient insights, salient information, and provide that to them so they can process it, reducing degrees of freedom for them to process it.Harry Glorikian: So just I mean, there are a lot of statistical tools out there now that that for managing risks in clinical trials. So how is the approach that you guys are taking either different or better or both.Rohit Nambisan: It's a good question. One way we've been able to address this question is that statistical approaches generally require certain amounts of data points to be collected before you can warrant using statistical parameters or assumptions, etc. And so there's two things at play here. On top of that, I just mentioned, we're moving into more specialized therapeutic areas, right? So patients per study are smaller, right. And on top of that, when you're starting out a study which is usually the riskiest points in the study, when you're early in the study to mid-stage in a study, you cross them with the fact that you have less patients and there are more niche studies, it's hard to find those patients. Now, your early phase, your riskiest phase, is going to be extended as compared to when you were developing against blockbuster indications. So for a long time in the study, you can't really reliably use statistical parameters to identify an outlier or identify something as aberrant. And then you need to focus on so the way we've done it, we've done it in a slightly different way. There's two approaches. One is we've actually developed a pretty complex risk score system that's based on a set of very different metrics. Think of it as like an array of different KPIs, right? Those KPIs will affect risk differently depending on the type of study you're in. And they'll have different weights to those risks of time, cost and quality depending on the study you're in. So we look at the given study, we're going to deploy and we say, okay, what are the features that characterize the study? Let's look in our historical repository against those same features, pull similar, we call look alike studies and we'll understand how to set those weightings to say protocol deviations at this point in the study are going to impact the overall quality of time. That's much more for this type of study. So we can basically, for lack of a better term, I guess the simplistic way of saying is we can augment the data that we have coming in from a study, which is small at the outset of the study, with lookalike data to increase the power. Right? So that's another way to look at this. So we can actually, we have much better power to be able to detect these issues earlier on and reliably confer that to clinical operators and clinical developers who can do something about it.Harry Glorikian: It would be nice if you had enough data at some point to almost run the whole trial in silico, in a sense. But I think we need a lot more data get there. But, just for everybody that's listening, sort of as a philosophical point, the reason we put drugs through clinical trials in humans is we simply don't know whether they'll work or what the unexpected side effect they might have once you start them on a much larger population. So in that sense, it's expected, even normal for some drugs, maybe even a lot of drugs, to fail at some point in phase one, phase two or phase three. And as an investor, you know, you don't want it to fail in phase three. You want it to fail early. So is Lokavant's goal to reduce the failures or simply help drug developers get to yes or no faster, safer, more cheaply?Rohit Nambisan: Yeah. So our approach has been initially get yes or no faster, safer, more cheaply, more efficiently, right. As part of that process and actually related to some of the work we have done in the last few months on monitoring scientific risk. Right. You have to be careful about these efficacy analyses because they can unblind the study, especially when you have single or double blind blinded studies. So you have to be careful about this point. But in some circumstances we can actually leverage our analysis on blinded endpoint analysis and understand how particular endpoints are collaborating or not collaborating or trending, to understand if there is any effect whatsoever that's being generated in the study. So this is early days for us. But to your to your point about the first use case, we are starting to think about that as an opportunity as well, because we found a way to effectively blind the information and still assess the information content to understand if there is any form of efficacy signal being produced. So I think that that is a really valuable way for us to approach the market in the near future. I think the other point here is that if you are cleaning the data, if you are identifying those data quality issues on a more real time basis, you should be able to reduce the time to do an interim analysis. Right. We should be able to -- you mentioned fail fast. Right. Failing fast requires you to also assess the data, to understand if there's an efficacy signal, there's a safety issue. And if we have these long cycle times before we can actually do an interim analysis. And much of the data indicates that those long cycle times are due to not knowing where the issues are and finding those issues then cleansing them. If we can do that faster, we should be able to do interim analysis much more frequently. Therefore, being able to generate a fail fast scenario.Harry Glorikian: You could almost, you should be able to set up the system to almost be running it and sort of move the bar on where it is on, “Looks successful,” or “It's moving down towards failure.” There's got to be some sort of almost real-time indicator as data is coming in to. You just don't want humans to jump the gun on that. The interesting thing is, I was looking at one of the blogs you have and you sort of say that one of the main reasons clinical trials are so costly and inefficient is bad data management and a lack of interoperability across data repositories. And, you know, it's funny because anybody who listens to this show knows that just comes up over. And it doesn't matter who you are in health care. It is a recurrent theme that for some reason people are not willing to step up and solve. I mean, it has to be a party like yours that comes in and helps clean it up from the outside as opposed to it being cleaned from the inside the way that you would ideally like it to be.[musical interlude]Harry Glorikian: Let's pause the conversation for a minute to talk about one small but important thing you can do, to help keep the podcast going. And that's leave a rating and a review for the show on Apple Podcasts.All you have to do is open the Apple Podcasts app on your smartphone, search for The Harry Glorikian Show, and scroll down to the Ratings & Reviews section. Tap the stars to rate the show, and then tap the link that says Write a Review to leave your comments. It'll only take a minute, but you'll be doing a lot to help other listeners discover the show.And one more thing. If you like the interviews we do here on the show I know you'll like my new book, The Future You: How Artificial Intelligence Can Help You Get Healthier, Stress Less, and Live Longer.It's a friendly and accessible tour of all the ways today's information technologies are helping us diagnose diseases faster, treat them more precisely, and create personalized diet and exercise programs to prevent them in the first place.The book is now available in print and ebook formats. Just go to Amazon or Barnes & Noble and search for The Future You by Harry Glorikian.And now, back to the show.[musical interlude]Harry Glorikian: So on this show we talk about, you know, how does analytics play into this? So, how do—and I've got to start finding new words—but AI and ML come into this picture. What types of tools in the AI toolbox is Lokavant using? What special powers does AI give you to extract predictions from your data set that other people don't?Rohit Nambisan: Yeah, I think I think the first piece is, and it's going to sound interesting in relation to what folks usually talk about in terms of AI and ML, but it's a harmonized data model, right? When I was working as a data scientist a number of years back, nobody told me all the work that you have to do with data governance and data harmonization. And then when you think about fast forward today where a lot of the actual models themselves are function calls, right? You realize that a lot of the work is actually making sure that data is ready to be analyzed for this particular use case. Right. So it's not to say that we don't do a number of different, try different approaches to gradient boosted descent or support vector machines or neural nets, which is actually my background in terms of grad school and research. But we spend a lot of time thinking through how we need to harmonize, create validated data pipelines to harmonize data for use. In this case. And even in that case, a lot of the work we do is a kind of intelligence or artificial intelligence. So when we're harmonizing the data, we're looking for views on leveraging multivariate clustering algorithms to actually figure out which particular types of data attributes should be mapped to one particular field.Rohit Nambisan: So it's not to say that the data harmonization is devoid of intelligent approaches, it is full of intelligent approaches, but it is an absolute necessity to have the integrity of the data that you need to run those sophisticated front end models, which we run a ton of. But I just I want to call attention to the fact that that is a core asset for Lokavant from the get-go, that Lokavant's canonical data model and the processes we use to harmonize data to get it into that state has been a core focus because if you can do that—and that is the same model you're providing to your data science and analytics teams, your product development teams—then you really have that flywheel that you can generate a number of different analyses. For example, I just mentioned that predictive enrollment forecast model that comes off of in our our Lokavant canonical data model. That is something that is a predictive model, leveraging historical data and ongoing study data in an automated model that indexes towards the historical data early in the trial, indexes towards prediction indexes towards ongoing study data as it comes in. And we have more confidence that input over the trial, that's like an emergent benefit of having the harmonized data harmonize.Harry Glorikian: So, you know, one has to ask in the age of the coronavirus, right, how has the business of running clinical trials changed since the pandemic? I mean. And how do you guys...is that an advantage or disadvantage? I'm trying to, you know, place where you guys are in the whole realm of how things have hopefully changed for the better.Rohit Nambisan: Yeah, it's been quite a tailwind for us actually. And I would say that, number one, it's been it's been beneficial to us because there's just been a lot more scrutiny and interest in clinical research. Not to say there wasn't before, especially for niche therapeutic areas, but and the fact that we were able to develop and get novel COVID vaccines out pretty rapidly. But there was also a lot of challenges along the way in getting to that point. And also delays and trials and challenges in therapeutics development to address COVID as well. So there's just been a lot of scrutiny in the last 24 to 30 months on how efficient and how fast and how effective clinical research can be. So just that alone has been beneficial. Now let's take the next step there and say that all associated with the pandemic, there's been a great impact to clinical trials across the board, not just COVID trials or therapeutic trials. Patients, participants couldn't get to sites for site data collection, right. Site staff couldn't get in there, too, for data entry or site management or site oversight activities. Right. So in general, it's been a huge boon to those technology groups that have developed, decentralized or direct-to-patient data capture methodologies, thereby lowering the patient burden and the site burden for clinical trials to continue in a pandemic fueled environment. What's interesting about that as well, when we think about ourselves as both a data type agnostic platform for clinical research as well as an analytics engine, a platform on top of that, you see this huge movement to another type of data, another data, for example, decentralized trial data as another data source.Rohit Nambisan: And what we've seen also is that while there's been a shift to a lot of decentralized trial collection on most studies, at least 90 percent of studies and above, they're hybrid, they're not fully decentralized. So you have to have some site data collection and you have some decentralized data collection. And that makes sense for those things that may make the most sense to lower patient and site burden to administer. Let the patient let the participant be at home. For those that require like biopsies, etc., that require a participant oftentimes to come into the site, let that be the site. The challenge there is now you have these two different complex data streams that are not necessarily harmonized and aggregated. So this is, again, I think that's been an area where we've been able to come in and say we'll just as a matter of course, you're doing business, this is another data set to us. We need to bring these two in and we have to also enable comparative analysis against decentralized and traditional site based data collection, because otherwise you're going to miss insights. You're going to miss information that are critical to your study.Harry Glorikian: Yeah, a part of me was just thinking, you know, you guys should buy somebody, like Unlearn AI and go at it together where you can have, you know virtualized patients that you can put into the trial, but that's… we won't go there. So let's step back for though, for a second. So let's talk about the company's origin story. Lokavant is one of many companies launch by Roivant, as you mentioned earlier. A Lot of the companies end up with the word “vant.” So can you explain so that people understand: What is Roivant, how it operates, what are vants and and why was Lokavant born. And how did you become president and CEO?Rohit Nambisan: Sure. So Roivant started about seven years ago. And I should mention Roivant is our parent company. We were founded out of Roivant and spun out as a technology company itself. So Roivant initially started as a company that launched "vants" -- nimble, entrepreneurial biotech companies and now health tech companies as well. When I joined Roivant three and a half years ago, Roivant had about 15 different biotech companies. And what was really interesting about their approach is it was therapy agnostic, so it was not that there was a strategic focus or oncology or strategic focus on immunology. There was a focus around identifying compounds that may have been deprioritized in larger pharma companies, which says pharma companies that had a lot of potential and had could address critically unmet clinical needs. And so Roivant would in-license those therapies and start a therapy therapeutically oriented vant. So at the time Axavant it was the new neurological oriented, neurological disease oriented vant. Myovant was the human reproductive oriented, disease oriented vant. Et Cetera. And so now when you think about somebody like myself who comes from the tech world and life sciences, health care technology world, brought into Roivant three and a half years ago, the premise behind Roivant at the time was we can more efficiently develop these therapeutics and have more favorable outcomes leveraging innovative ways of addressing human talent as well as technology. And that latter piece is where obviously I came in and we were starting to look at in my team what are some of the most significant challenges and frequent challenges amongst the vants themselves in running these clinical trials? And then does that map against some of the more significant frequent challenges we see outside in the market? And not surprisingly, there were quite a few particular areas of resonance.Rohit Nambisan: At that point in time, they're about 54, 45 programs being run by Roivant. And so it was across a variety of therapeutic areas. And I guess the thing that hit us in the face primarily was I guess the best way I could say it is you can order a pizza, right? You can understand what is it, a $25 investment, $20 investment. Maybe it's gone up since then, since I ordered a pizza. But the point is that you can understand what time it was ordered, when it was when they said they were going to deliver it to you, and you can track it. And most of these apps now [show it] along its destination to a chain of custody to get to you. We were we could spend $3 to $50 million on any given trial and we were at struggling with our partners to actually identify what is the current state of enrollment in the last week? What is the current state of discontinuation? Where are we at with our with these particular sites in this region? Why are we seeing high screen failure rates, etc.? Right. That's egregious to me. That's just that should not be the case.Rohit Nambisan: We are fairly frustrated with that. And then even when we when even at Roivant or even in my former experiences at Novartis or other pharma, when we brought in a source system to say, okay, well, we're going to have a representation of data ourselves, right? So that we can understand what's going on. Invariably what happened is you would have one source system here and then a duplicate version of that sort of system at the CRO or another vendor that's working with you. You spent your entire time trying to figure out which was the source of truth, because they're spending all your time doing data reconciliation, saying, is that really accurate? Is that really the signal? So that didn't work either. So we felt pretty frustrated about this. We initially tried not to build it ourselves. We worked with a few different collaborators outside of Roivant and tech vendors, etc., and we were fairly frustrated with what we came back with there. So at that point we started thinking, if we can't buy it, we need to take a lead user innovation approach to address this. So we started out with the data platform, as I mentioned to you, and we built that capability to connect, ingest and map from any source, deliver that within a canonical data model, one single canonical data model. And then initially we did a bunch of bespoke analysis on top of that for a few different biotech vants. Rohit Nambisan: That went really well. Some of the external collaborators looked to Roivant at that point we said we'd like to work with this technology outside of the Roivant family, and we realized we were on to something, and we externally launched the company in January of 2020, which was very interesting time and year to launch a company. That being said, we spent the first, I'd say, just under two years, really focused on externally subsidized R&D phase. We're pretty fortunate to have some partners that invested in us in that phase, and we focused on first one particular application in response and we talked a lot about risk. But then we also realized that the needs across different companies, different vendors, etc. for managing clinical trials are very varied. So we realized what we need to really build as generalized on that first application we built and create a highly configurable analytics platform on top of this data platform so that we could actually analyze many different things and configure it for use for any particular customer. And so now we built across, I'd say seven or six or seven different use cases now, and we've deployed most of them and we're continuing to aggregate information in a true product sense where the biggest pain points in the market and how do we build or configure a version of the platform and the platform to address that. And at the same time, we're delivering on global trials with a number of pharma studies as well as on the side of the vendors working through them to deploy on studies as well.Harry Glorikian: So in a perfect world, right, if you had access to all the relevant data, if every drug developer in the world was taking advantage of your services, how would it change the business of clinical trials? What would the outcomes look like? Would it be like you get more drugs approved every year, at a lower cost, fewer disaster failures, I mean. What changes for the industry and for patients?Rohit Nambisan: Yeah. I think the first piece is you would reduce—and this is a lofty question so I'm going to answer with a lofty response—the first thing to note is that, and we touched on this earlier, I think you'd see fewer bigger failures in the analytics phase. You'd be able to identify earlier on, both in terms of the lifecycle of a compound, right? So from phase one to phase three or even phase four, but especially within the study itself, you'd be able to identify that there would be an issue in the study earlier on and you could kill it early on. So that's one one aspect I think would be that's important to note. The other thing I think you would identify is less operational issues. So I think one in six trials across the globe failed just because of operational issues. And when I mean operational issues, I mean the protocol and the plans at the outset of a study say need to administer the study following these steps. And when those steps are not followed, there's compliance risk. And therefore, when there's enough compliance rates to throw out the data or you have to not submit the study.Rohit Nambisan: And so one in six is, it's not that small. And so if we're tracking, if we're more rigorously tracking both what is happening and what could happen, right, based on the indication, leading indicators of risk across time, cost and quality, we should basically never see -- that's a that's one of our major goals -- never see a trial fail just because of an operational reason. Not to mention, how can you go to the patients with unmet clinical needs in a particular indication in particular disease and say, “Oh, I'm sorry, while the drug probably was effective, we just couldn't get it out into the market this time. And it's going to take us another trial, potentially.” A lot of times folks don't actually resurrect the failed study, a failed therapy. So even if they resurrected it and said it was because of an operational issue, “Oh, you've got to wait another six years.” That's just not acceptable. So I think those are the two components that come top of mind. And I think early in our in our tenure, our mission was no trial should fail due to operational error.Harry Glorikian: What is the path to financial success for a company like Lokavant? Is it to just keep growing? To go public? To get acquired by a maybe by a big pharma. What's the path?Rohit Nambisan: It's a good question. I think folks that that know exactly what their exit strategy are probably, for lack of a better term, often deluded. But I will say that we've seen a lot of growth. Not only during, there's been a lot of interest in Lokavant during the pandemic, I mentioned we were in this externally subsidized R&D phase, we were actively trying not to do too much externally. We wanted to figure out how to set up the platform for success. Coming out of that phase, in the last six months, we've seen an incredible amount of traction externally. And so I think we are still in the path of doing it on a growth trajectory ourselves. What does that mean in terms of opportunities to collaborate both commercially and partner and strategically? Well, it means that we can only do as much as we can, even if we continue to grow. There's data out in the market and partners that have access to that data that we would love to collaborate with. If that means that we need to be more strategic in our approach to what Lokavant can do or how to structure Lokavant, we'll do that just because we need to actually achieve our mission, which is to have no trials fail due to operate operational error. Right. And so I think that requires more data. That requires more data science. We have a lean, very, very proficient data science team. So I think there will be opportunities for strategic collaboration, but it's all related to the mission of bringing this clinical trial intelligence platform to address operational and other risks in a study as effectively as possible.Harry Glorikian: You know, one of the things that crosses my mind is you could also use this from an investing perspective to analyze a trial that's going through its paces against historical information and determine, give it a weighting of probability of success versus failure from an investment perspective, that that seems attractive to me.Rohit Nambisan: Yeah. So that's an interesting point to bring up. There are folks now asking us in the market about what we've been informed firmly in trial execution stage. Folks are asking us to move into feasibility and effectively feasibility. Is that the planning of the study? Tell me with this particular configuration of sites, countries and for this indication, knowing the standard of care in different countries, knowing the approach to clinical care, not just clinical research, how successful would this study be? Right. And obviously, the success of a study, when you think about biotech, the success of a study is the success of the company. When you think when you go up the market, depending on the study, it can still have incredible impacts, the success of the company. So there is definitely an afferent towards the investing world and financial. I think at first we probably take a progressive step towards that by moving into trial planning analytics in this manner and then validating our approach against progress in space and seeing how we can continue to grow in that sector.Harry Glorikian: Well, Rohit, it was great having you on the show. I hope everybody enjoyed our discussion. You know, a lot of problems to solve in this industry. So there's there's no lack of opportunity from, you know, businesses that need to get started and the data that needs to be optimized to help move the process forward. But, you know, luckily, everybody I talk to on the show, that's the direction we're all moving. So hopefully we'll get there faster, because I'm not getting any younger. So, so good drugs are going to be needed at some point. So good to have you here. And I can't wish you and the team at Lokavant, you know, more success.Rohit Nambisan: Thanks, Harry, for having me on the show. It was wonderful to be here.Harry Glorikian: That's it for this week's episode. You can find a full transcript of this episode as well as the full archive of episodes of The Harry Glorikian Show and MoneyBall Medicine at our website. Just go to glorikian.com and click on the tab Podcasts.I'd like to thank our listeners for boosting The Harry Glorikian Show into the top three percent of global podcasts.If you want to be sure to get every new episode of the show automatically, be sure to open Apple Podcasts or your favorite podcast player and hit follow or subscribe. Don't forget to leave us a rating and review on Apple Podcasts. And we always love to hear from listeners on Twitter, where you can find me at hglorikian.Thanks for listening, stay healthy, and be sure to tune in two weeks from now for our next interview.

We kick off the Spring 2022 semester with a panel discussion on the future of American politics after Dobbs v. Jackson, "What Happens if Roe is (Not) Overturned?". Featuring former Congressman Dan Lipinski (D-IL), Prof. Sherif Girgis (ND Law School), and Prof. Christina Wolbrecht (ND Political Science), conversation will focus on the potential political and legal outcomes of one of the Supreme Court's most controversial cases of this term. Vivek Ramaswamy is a New York Times bestselling author and entrepreneur who has founded multiple successful enterprises. A first-generation American, he is the founder and Executive Chairman of Roivant Sciences, a new type of biopharmaceutical company focused on the application of technology to drug development. He founded Roivant in 2014 and led the largest biotech IPOs of 2015 and 2016, eventually culminating in successful clinical trials in multiple disease areas that led to FDA-approved products. Mr. Ramaswamy was born and raised in southwest Ohio. He graduated summa cum laude in biology from Harvard in 2007 and began his career as a biotech investor at a prominent hedge fund. Mr. Ramaswamy continued to work as an investor while earning his law degree at Yale, where he was a recipient of the Paul and Daisy Soros Fellowship for New Americans. He was featured on the cover of Forbes magazine in 2015 for his work in drug development. In 2020 he emerged as a prominent national commentator on stakeholder capitalism, free speech, and woke culture. He has authored numerous articles and op-eds, which have appeared in the Wall Street Journal, National Review, Newsweek, and Harvard Business Review. Mr. Ramaswamy serves on the board of directors of the Philanthropy Roundtable and the Foundation for Research on Equal Opportunity.

Welcome to Season 4 of The Right Idea Podcast: “Fight for America.” Our country's future is on the line and it's time to do something about it. In this season, we'll focus on building a better future for us all by fighting for America.  In today's episode, Vivek explains and defines critical race theory, woke culture & cancel culture, he talks about his new book WOKE INC. where he writes about his first-hand experiences in elite, corporate America, and he explains his belief that the biggest threat to liberty and prosperity in America today is the hybrid of big government and big business – where he says that together, they can do more than what either can do on its own to restrain the liberty of everyday Americans. Vivek is a first-generation American, the anti-woke author of WOKE, INC., and the founder and executive chairman of Roivant Sciences, a new type of biopharmaceutical company focused on the application of technology to drug development. Host: Kevin Nicholson, President & CEO of No Better Friend Corp.Speakers: Vivek Ramaswamy - New York Times bestselling author and successful biotech entrepreneur Producers: Darryl Carlson, Executive Director & Courtney Mullen, Communications Director

Join us for a lecture by Vivek Ramaswamy on his new bestselling book, "Woke, Inc.: Inside Corporate America's Social Justice Scam." Vivek Ramaswamy is a New York Times bestselling author and entrepreneur who has founded multiple successful enterprises. A first-generation American, he is the founder and Executive Chairman of Roivant Sciences, a new type of biopharmaceutical company focused on the application of technology to drug development. He founded Roivant in 2014 and led the largest biotech IPOs of 2015 and 2016, eventually culminating in successful clinical trials in multiple disease areas that led to FDA-approved products. Mr. Ramaswamy was born and raised in southwest Ohio. He graduated summa cum laude in biology from Harvard in 2007 and began his career as a biotech investor at a prominent hedge fund. Mr. Ramaswamy continued to work as an investor while earning his law degree at Yale, where he was a recipient of the Paul and Daisy Soros Fellowship for New Americans. He was featured on the cover of Forbes magazine in 2015 for his work in drug development. In 2020 he emerged as a prominent national commentator on stakeholder capitalism, free speech, and woke culture. He has authored numerous articles and op-eds, which have appeared in the Wall Street Journal, National Review, Newsweek, and Harvard Business Review. Mr. Ramaswamy serves on the board of directors of the Philanthropy Roundtable and the Foundation for Research on Equal Opportunity.

Lindsay Androski is the President and CEO of Roivant Social Ventures (RSV): a 501(c)(3) social impact organization started by leaders from Roivant Sciences. RSV takes a venture philanthropy approach to investing in and incubating promising health initiatives. Prior to her initiation into the life sciences industry, Lindsay utilitized her degrees from M.I.T. as a trial lawyer and an Assistant U.S. Attorney in Alexandria, Virginia, where she led investigations and prosecutions of high-profile cybercrime and national security cases and received the highest awards given by several federal agencies. In this episode, Lindsay tells John about her journey, about social impact in the life sciences industry (as well as why it is important to her) and about the future of science as a process and as product. 

➡️ Like The Show? Leave A Rating: https://ratethispodcast.com/successstory ➡️ About The Guest Vivek Ramaswamy is a successful entrepreneur who has founded multiple successful enterprises. A first-generation American, he is the founder and Executive Chairman of Roivant Sciences, a new type of biopharmaceutical company focused on the application of technology to drug development. He founded Roivant in 2014 and led the largest biotech IPOs of 2015 and 2016, eventually culminating in successful clinical trials in multiple disease areas that led to FDA-approved products. Vivek was featured on the cover of Forbes magazine in 2015 for his work in drug development. In 2020 he emerged as a prominent national commentator on stakeholder capitalism, free speech, and woke culture. He has authored numerous articles and op-eds, which have appeared in the Wall Street Journal, National Review, Newsweek, and Harvard Business Review. ➡️ Talking Points 00:00 - Vivek's Story. 09:08 - Shareholder vs. stakeholder capitalism. 13:18 - How did wokeness start? 22:03 - Goldman Sachs & diversity. 29:06 - The separation of church and state. 36:29 - What's the fix for corporate greed? 41:27 - Critical Race Theory & wokeness. 46:53 - Entrepreneurial lessons from one of the largest biotech IPO's. ➡️ Show Links https://www.instagram.com/vivekgramaswamy/ https://twitter.com/vivekgramaswamy https://amzn.to/3c2AV30 ➡️ Podcast Sponsors 1. Better Help —Virtual Therapy & Mental Wellness https://betterhelp.com/scottclary — 10% Off First Month 2. True Bill—Control Your Subscriptions https://truebill.com/successstory 3. Nutrafol —Increase Hair Thickness & Volume https://nutrafol.com/ (CODE: successstory) — $15 Off First Month 4. Hubspot Podcast Network https://hubspot.com/podcastnetwork

We discuss woke capitalism, interdisciplinary pursuits, entrepreneurship, the biotech and asset management industries, the need for passion in life, happiness, career changes, and life stages among other topics. _______________________________________ Vivek is the author of the recently released New York Times bestseller book Woke, Inc.: Inside Corporate America's Social Justice Scam. He founded and served as executive chairman of Roivant Sciences, a biopharmaceutical company specializing in the use of technology to drug development. In 2016, Forbes Magazine listed Vivek as the 24th richest American entrepreneur under 40 (net worth of $600 million). He holds a Harvard undergraduate degree in biology and a Yale University law degree. _______________________________________ If you appreciate my work and would like to support it: https://subscribestar.com/the-saad-truth https://patreon.com/GadSaad https://paypal.me/GadSaad _______________________________________ This chat was posted earlier today (October 6, 2021) on my YouTube channel as THE SAAD TRUTH_1309: https://youtu.be/uy5cee96yAE _______________________________________ The Parasitic Mind: How Infectious Ideas Are Killing Common Sense (paperback edition) was released on October 5, 2021. Order your copy now. https://www.amazon.com/Parasitic-Mind-Infectious-Killing-Common/dp/162157959X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= https://www.amazon.ca/Parasitic-Mind-Infectious-Killing-Common/dp/162157959X https://www.amazon.co.uk/Parasitic-Mind-Infectious-Killing-Common/dp/162157959X _______________________________________ Please visit my website gadsaad.com, and sign up for alerts. If you appreciate my content, click on the "Support My Work" button. I count on my fans to support my efforts. You can donate via Patreon, PayPal, and/or SubscribeStar. _______________________________________ Dr. Gad Saad is a professor, evolutionary behavioral scientist, and author who pioneered the use of evolutionary psychology in marketing and consumer behavior. In addition to his scientific work, Dr. Saad is a leading public intellectual who often writes and speaks about idea pathogens that are destroying logic, science, reason, and common sense. _______________________________________  

We discuss woke capitalism, interdisciplinary pursuits, entrepreneurship, the biotech and asset management industries, the need for passion in life, happiness, career changes, and life stages among other topics. _______________________________________ Vivek is the author of the recently released New York Times bestseller book Woke, Inc.: Inside Corporate America's Social Justice Scam. He founded and served as executive chairman of Roivant Sciences, a biopharmaceutical company specializing in the use of technology to drug development. In 2016, Forbes Magazine listed Vivek as the 24th richest American entrepreneur under 40 (net worth of $600 million). He holds a Harvard undergraduate degree in biology and a Yale University law degree. _______________________________________ If you appreciate my work and would like to support it: https://subscribestar.com/the-saad-truth https://patreon.com/GadSaad https://paypal.me/GadSaad _______________________________________ This chat was posted earlier today (October 6, 2021) on my YouTube channel as THE SAAD TRUTH_1309: https://youtu.be/uy5cee96yAE _______________________________________ The Parasitic Mind: How Infectious Ideas Are Killing Common Sense (paperback edition) was released on October 5, 2021. Order your copy now. https://www.amazon.com/Parasitic-Mind-Infectious-Killing-Common/dp/162157959X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= https://www.amazon.ca/Parasitic-Mind-Infectious-Killing-Common/dp/162157959X https://www.amazon.co.uk/Parasitic-Mind-Infectious-Killing-Common/dp/162157959X _______________________________________ Please visit my website gadsaad.com, and sign up for alerts. If you appreciate my content, click on the "Support My Work" button. I count on my fans to support my efforts. You can donate via Patreon, PayPal, and/or SubscribeStar. _______________________________________ Dr. Gad Saad is a professor, evolutionary behavioral scientist, and author who pioneered the use of evolutionary psychology in marketing and consumer behavior. In addition to his scientific work, Dr. Saad is a leading public intellectual who often writes and speaks about idea pathogens that are destroying logic, science, reason, and common sense. _______________________________________  

“The biggest threat to liberty and prosperity in this country” is the “new marriage of big government and big business,” says Vivek Ramaswamy. “It is this new https://www.theepochtimes.com/t-woke (woke) industrial complex… a new Leviathan.” Ramaswamy is the founder of several successful companies, including Roivant Sciences, and author of the new book “Woke, Inc.: Inside Corporate America's Social Justice Scam.” It's crony capitalism 2.0, Ramaswamy argues. And the biggest beneficiary of all is the Chinese Communist Party, he says. Thank you American Hartford Gold for sponsoring American Thought Leaders. There are still companies like American Hartford Gold, that value freedom of speech and honest discourse—and are sponsoring shows like ours. With inflation on the rise, investing in gold is another option to diversify your assets. American Hartford Gold is a patriotic, family-owned company that not only sells precious metals right to your front door, they can help deposit gold into a retirement account like an IRA or 401K. They've got an A+ rating with the Better Business Bureau, and right now they have a promotion where they will give you up to $1,500 of free silver on your first order. You can just call 855-862-3377, that's 855-862-3377 or you can text “AMERICAN” to 6-5-5-3-2.

“The biggest threat to liberty and prosperity in this country” is the “new marriage of big government and big business,” says Vivek Ramaswamy. “It is this new woke industrial complex… a new Leviathan.”Ramaswamy is the founder of several successful companies, including Roivant Sciences, and author of the new book “Woke, Inc.: Inside Corporate America's Social Justice Scam.”It's crony capitalism 2.0, Ramaswamy argues. And the biggest beneficiary of all is the Chinese Communist Party, he says.Thank you American Hartford Gold for sponsoring American Thought Leaders.There are still companies like American Hartford Gold, that value freedom of speech and honest discourse—and are sponsoring shows like ours.With inflation on the rise, investing in gold is another option to diversify your assets. American Hartford Gold is a patriotic, family-owned company that not only sells precious metals right to your front door, they can help deposit gold into a retirement account like an IRA or 401K.They've got an A+ rating with the Better Business Bureau, and right now they have a promotion where they will give you up to $1,500 of free silver on your first order. You can just call 855-862-3377, that's 855-862-3377 or you can text “AMERICAN” to 6-5-5-3-2.

Guests: Dr. Frank Sorrentino, Political Science Expert, On to discuss the the major events of the week. Vivek Ramaswamy, Founder and CEO of Roivant Sciences, On to discuss his book "Woke Inc." And ... Your thoughts on the latest in the news! See omnystudio.com/listener for privacy information.

This week, Shannon sits down with entrepreneur, author, and founder of the Roivant Sciences, Vivek Ramaswamy, to discuss his new book Woke, Inc.: Inside Corporate America's Social Justice Scam.  Vivek shares how corporations have become a major influence on most Americans' opinions on social issues, which leads to fear of expressing their true beliefs, and ultimately is detrimental to society.  Follow Shannon on Twitter: @ShannonBream 

Vivek Ramaswamy, Executive Chairman of Roivant Sciences and author of Woke, Inc.: Inside Corporate America's Social Justice Scam, joins The Realignment to debate whether companies should take stands on issues like Black Lives Matter, Hong Kong, Taiwan, and other political issues, the social contract between corporations and the public, and the role of identity in a hyper-polarized America.

Raquel Crystal is Head of Human Resources & Operations at Sio Gene Therapies (f/k/a Axovant Gene Therapies). Ms. Crystal has 15 years of human resources experience across different industries. She previously served as Head of Human Resources and Talent Acquisition at Roivant Sciences, Inc. Prior to that, Ms. Crystal was the Head of Human Resources for CoreOne Technologies, LLC, a financial technology firm, covering Europe, Asia and North America.  She also held multiple roles in human resources at Morgan Stanley and Ambrose Employer Group, LLC.  She holds a B.S. in Industrial and Labor Relations from Cornell University.

Listen to our conversation with the executive chairman and founder of Roivant Sciences. Learn how Mr. Ramaswamy used his experience in Biotech investing to found a 7 billion dollar company, and what his insights are regarding building a start-up and how Covid-19 has impacted the industry.

Sumitomo Dainippon Pharma's $3 billion strategic transaction with Roivant Sciences that gave rise to Sumitovant, represents an effort by the Japanese drug company to make the drug development process faster and more efficient. A critical piece of this effort is steps the company has taken to harness information technology to capitalize on existing knowledge to inform decision making. We spoke to Bill McMahon, chief algorithmic analytics officer of Sumitovant, about the approach Sumitovant is taking, the way uses information technology to improve the drug development process, and how the subsidiary may be influencing the way its parent company operates.

Lanny Sun, co-founder of Silicon Therapeutics, recently acquired by Roivant Sciences. speaks with corporate branding veteran John Simboli about leadership in biopharma. Lanny also discusses how Silicon Therapeutics, now part of Roivant Drug Discovery, is advancing its chip-to-clinic, computational quantum physics-based approach to pioneer a new path for drug design of  medicines to improve the lives of patients

Ayaan talks with Vivek Ramaswamy about essentialism, stakeholder vs. shareholder capitalism, and American freedom. They dive into Vivek's background, discuss the dangers of wokeism and idea fixing, and explore ways of addressing inequality. Vivek Ramaswamy is the Founder and Chief Executive Officer of Roivant Sciences and the author of the forthcoming book “Woke Inc.: Inside Corporate America's... Source

Ayaan talks with Vivek Ramaswamy about essentialism, stakeholder vs. shareholder capitalism, and American freedom. They dive into Vivek’s background, discuss the dangers of wokeism and idea fixing, and explore ways of addressing inequality. Vivek Ramaswamy is the Founder and Chief Executive Officer of Roivant Sciences and the author of the forthcoming book “Woke Inc.: Inside […]

Drug Development is a challenging process. It needs profound basic research, translating scientific results into products and moving them towards the market.Making things more challenging deal structuring is also a b2b business, which means selling products to the pharma industry that completes the product development and brings therapeutics to patients.How does structuring deals with the pharma industry really work to sign one of those multi-billion dollar contracts?Sascha Bucher is a Venture Capital expert with tremendous experience in deal structuring with the pharmaceutical industry.In his career at renowned venture funds and companies like Roivant Sciences, Roche, or UBS, he completed transactions worth more than 10 billion dollars.To give life science entrepreneurs access to the expertise, network, and funding, he and his team are in the process of founding Forty51 Ventures - a novel venture fund dedicated to closing the Life Science Valley of Death in Central Europe.Join our conversation and learn more about how to negotiate with the pharmaceutical industry.Gain more insights into VCs' daily business life with a particular focus on building relationships with BD, R&D, and C-suite executives in the industry.Link to the Video of the Recording:YouTubeSpeaker:Astrid WoollardChristian SoschnerSascha BucherOrganizations:CS Life Science InvestForty51 VenturesScytale VenturesBe part of our Network:Subscribe here: https://mailchi.mp/e2467061ef75/lsg2gSupport the show (https://www.lifescienceget2gether.com/registration-membersclub/)

Julie Kelly, is a political commentator and senior contributor to American Greatness. She is the author of Disloyal Opposition: How the NeverTrump Right Tried―And Failed―To Take Down the President and Vivek Ramaswamy, CEO of biotech company Roivant Sciences and author of the forthcoming book WOKE INC (Center Street, 2021), is out with a new op-ed out today in the WSJ: Save the Constitution From Big Tech -- which addresses these latest restrictions by Big Tech. In his op-ed, Ramaswamy asserts that it sets a dangerous precedent for Silicon Valley CEOs like Mark Zuckerberg and Jack Dorsey to wield greater judgment in communicating with the American people than the President of the United States. To curb their intrusion on free speech, he argues, Big Tech companies should be treated as state actors when they engage in selective regulation of political speech.  The Sean Hannity Show is on weekdays from 3 pm to 6 pm ET on iHeartRadio and Hannity.com. Learn more about your ad-choices at https://news.iheart.com/podcast-advertisers

Everybody comes in touch with the life science industry. Hardly anybody knew about the challenges, and hardships scientists have to overcome to bring a product from the university-level to the market.Since the outbreak of SARS-CoV-2, more and more people are becoming interested in life science investments. And ask the question: How does that work?In this episode, I am talking with entrepreneurs and investors from the LSG2G network. How do life science investments work? What are investors looking at? Is the life science industry right for Business Angels? What does it take to bring a product to the market?All these questions I discussed with the keynote speaker and panelists.Speaker:Andreas Grassauer (https://www.linkedin.com/in/andreas-grassauer-048843b2/)Astrid Woollard (https://www.linkedin.com/in/astridwoollard/)Christian Soschner (https://www.linkedin.com/in/christiansoschner/)Christopher de Souza (https://www.linkedin.com/in/cdesouza1/)Henriette Lininger (https://www.linkedin.com/in/henriette-lininger-90759615/)Sara Núñez-Garcia (https://www.linkedin.com/in/sara-n%C3%BA%C3%B1ez-garcia-phd-mba-00141a3/)Walter Stockinger (https://www.linkedin.com/in/walter-stockinger-dr-13b1a4b/)Companies:Broadview Ventures (https://www.linkedin.com/company/broadview-ventures-inc/about/)CS Life Science Invest (https://www.cslifescienceinvest.com/)Hadean Ventures (https://www.linkedin.com/company/hadean-ventures/)LSG2G (https://www.lifescienceget2gether.com/)Roivant Sciences (https://roivant.com/)Scytale Ventures (https://www.linkedin.com/company/scytale-ventures/)Vienna Stock Exchange (https://www.linkedin.com/company/wiener-borse-ag/)Do you want to learn more about life science?Join exclusive future webinars and member-only events: Become a member of the LSG2G Network. Join today: https://www.lifescienceget2gether.com/registration-membersclub/

On this episode of The Business Of Biotech, we're talking with Vivek Ramaswamy, who launched Roivant Sciences—parent company to a full 20 biopharma companies with dozens of pre-clinical through phase 3 candidates in their collective pipelines—back in 2014. Spinning them all up so quickly has required a skillful approach to recruiting—and maintaining—the company’s talent pool.Listen in as Ramaswamy walks through the art, science, and nuance of building an all-star biotech team.

Vivek Ramaswamy Founder and CEO, Roivant Sciences “Seeing my own family members in New York go through what they're going through has...not only turned our personal life upside down, but also has turned upside down...the near-term priorities of our company to help do our part in addressing this pandemic.” When Vivek Ramaswamy was only 28, he founded the pharmaceutical company Roivant Sciences. When COVID-19 hit New York City, his wife was a frontline medical worker—and pregnant with their son. The child was born healthy, but his wife and father-in-law soon tested positive for the virus. They are still recovering. As Ramaswamy manages his company from a home in Ohio, the man who graduated summa cum laude from Harvard muses on life's hard-earned lessons: “Things don't always go as you expected, but you rise to the occasion in the best way you can.”

Vivek Ramaswamy is the founder and CEO of Roivant Sciences, the parent of a growing family of companies focused on diverse areas including women’s health, rare diseases, neurology, cardiometabolic diseases, urology, dermatology, RNA therapeutics, and healthcare data.  Learn more about the CNS Summit and follow us on Twitter (@cnssummit). Listen to this episode on Health Podcast Network.

In 2017, Anirudh was diagnosed with a rare blood disease that threatened to derail his life. Anirudh shares the incredible story of how he battled the disease twice, receiving two bone marrow transplants, before setting on his path to recovery. As a rising star in the healthcare policy field, and having experienced first hand the challenges of healthcare in America, Anirudh is one of the best young voices on healthcare policy reform. Anurag and Anirudh chat about America's healtcare system, a move towards value-based healthcare, and other innovations in the field. Anirudh Srirangam works at Roivant Sciences, a healthcare company based in New York City. His mission is to increase access to high quality, high value healthcare for patients in need.

Roivant Sciences doesn't fit easily into conceptions of drug companies, venture capital firms, or accelerators. It is building highly-focused drug development companies around promising undervalued assets it licenses. In five years' time, it's raised more than $3 billion, amassed a broad pipeline of more than 35 therapies, and has more than 800 employees. We spoke to Eric Venker, chief operating officer of Roivant, about the company's business model, how it leverages its resources, and how it may be changing the industry's approach to drug development.

Today in FirstWord:

We talked a lot about SoftBank’s Vision Fund last week and about how it invested $2.5bn in e-commerce marketplace Flipkart, led a $1.1bn round for life sciences and healthcare technology developer Roivant Sciences and hooked up with its parent company to inject $1bn into sports e-commerce platform Fanatics. But if you want more insight into … Continue reading "21 August 2017 – $1.7bn Chinese EV Investment"

Founder and CEO of Roivant Sciences, 31-year-old Vivek Ramaswamy, goes deep into the workings of the pharmaceutical industry. He explores questions including: Why take on Alzheimers when other big pharmaceuticals aren't? Why have there been so few changes in drug development for women's health? And why he's willing to take the financial risk of investing in drug research that fails.